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Abstract 
The aim of the pre-eclampsia (PE) and eclampsia monitoring, prevention and treatment consortium 
is to develop a rapid diagnostic test for PE in pregnant women because early identification of PE 
would decrease the likelihood of maternal and perinatal mortality and improve antenatal care, 
management and treatment. The identification of potential bio-markers is thus of great importance in 
PE because urine is a non-invasive bio-specimen and has the potential to help predict PE since 
proteinuria can be detected and quantified in urine. The purpose of this exploratory study was to 
evaluate the long-term stability of selected analytes within preservative-free urine in a pre-eclampsia 
cohort.  
Calcium, Creatinine and total protein in long-term, stored urine samples were measured using both 
manual Siemens and Life Assay dipsticks and compared with high-throughput, laboratory 
measurements. Additionally, the diagnostic and prognostic potential of an Enzyme-linked 
immunosorbent assay (ELISA) -based, Adipsin or Complement Factor D (CFD) test for pre-
eclampsia was evaluated. Furthermore, fresh urine samples were collected, and different processing 
and intermediate storage conditions were evaluated and compared to the medical research gold 
standard to determine to what extent pre-analytical variables could affect sample integrity. Albumin, 
Creatinine, Calcium, Urea and Total Protein were measured using high-throughput measurements. 
The results of the study showed that the measurements for the Siemen dipstick and Life Assay dipstick 
were significantly similar. However, no agreement was found between the dipsticks and high-
throughput laboratory measurements. Adipsin was measurable using the ELISA assay despite the 
assay not being validated for frozen urine samples. Our results also showed that the measurements 
for Creatinine, Protein, and Calcium were impacted after sample storage at room temperature for 48 
hours, highlighting pre-analytical variable has a great influence on sample integrity. 
This exploratory pilot study provided insight into the sample collection, handling, processing and 
long-term storage of urine bio-specimens and how each step of the process can have an impact. These 
insights led to an understanding of the limitations of this pilot study and can help to establish priorities 
for a larger study in terms of selected analytes to be measured, that could improve final research 
design and determine the best methods for data collection and analysis. 
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Opsomming 
Die Pre-eklampsia (PE) en eklampsia monitering, voorkomings- en behandelings konsortium beoog 
om 'n vinnige diagnostiese toets vir PE in swanger vroue te ontwikkel, aangesien vroeë identifikasie 
van PE die waarskynlikheid van moeder- en perinatale sterftes verminder en voorgeboortelike sorg, 
bestuur en behandeling verbeter. Die identifisering van potensiële biomarkers is dus van groot belang 
in PE aangesien urine 'n nie-indringende bio-monster het die potensiaal om PE te help voorspel, 
aangesien proteïurie in urine opgespoor kan word en gekwantifiseer kan word. Die huidige 
loodsstudie was om die langtermyn stabiliteit van selekteerde metabolite in nie-gepreserveerde uriene 
in n PE kohort te evalueer. 
Totale proteïen, kalsium en kreatinien in lang termyn gestoorde uriene was gemeet met die gebruik 
van die Siemens en Life Assay Dipstick en vergelyk met hoë-deurset laboratorium analise. 
Terselfdertyd, die diagnostiese en prognostiese potensiaal van n ELISA gebasseerde 
Adipsin/Komplement Faktor D (KFD) toets vir PE was ook geevalueer. Vars uriene was ook 
gekollekteer en op verskillende maniere geprosesseer en tydelik gestoor. Die verskillende kondisies 
was geevalueer en vergelyk met die goue standard om te bepaal tot watter punt voor –analitiese 
veranderinge monster intergiteit affekteer. Albumin, Kreatinien, Kalsium, Ureum en Totale Proteïen 
was gemeet deur hoë-deurset laboratorium metings. 
Die studieuitslae toon dat die metings vir die Siemen en die LifeAssay dipstiek aansienlik gelyk is 
maar geen ooreenkoms was tussen die dipstieks en die hoë-deurvoer resultate gevind nie. Dus word 
verdere navorsing en valideringstudies voorgestel. Adipsin kon gemeet word deur die ELISA-toets 
te gebruik, ondanks die feit dat die toets nie vir urienmonsters valideer is nie. Ons resultate wys ook 
dat monsters wat by kamertemperatuur vir 48 uur gestoor is, het n invloed op die metings vir 
Kreatinien, Proteïen en Kalsium en beklemtoon dat voor –analitiese veranderinge n groot invloed het 
op monster integriteit. 
Die verkennende studie het insig gegee in die versameling, hantering, verwerking en lang termyn 
storing van uriene monsters en hoe elke stap van die proses 'n impak kan hê. Hierdie insigte het ons 
begrip gegee van die beperkings van hierdie loodsstudie en sal help om prioriteite te vestig vir die 
groter studie in terme van die meting van  selekteerde metaboliete, die verbetering van die finale 
navorsingsontwerp en die bepaling van die beste data-insameling en analise metodes 
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Chapter 1  
Introduction and Literature Review 
1.1. Introduction 
A bio-bank is a research infrastructure that aids in research support, scientific advancement and 
innovation by providing a collection of high-quality, biological samples or bio-specimens that are 
stored temporarily or long term together with their associated data (Baker, 2012). Bio-specimens can 
be any type of biological sample, such as blood, eggs, sperm, hair, nucleic acid, urine, saliva, tissue 
etc. in which biological molecules or bio-markers can be found.  
Today, bio-markers are becoming more important because they can serve as a measurable indicator 
to measure normal biological processes, the presence or progress of disease (pathogenesis), or the 
effects of treatment. However, bio-marker discovery and validation remain challenging owing to 
small sample sizes, low-quality bio-specimens and poorly captured clinical data. Access to high-
quality bio-specimens with associated clinical data of high statistical reliability are required for 
validation purposes, and this is where a bio-bank is key as a tool. In a bio-bank it is possible to ensure 
strict application of standardised protocols and quality control (QC) and to address the effects of pre-
analytical and storage variables. 
There have been many studies focused on long-term storage of bio-specimens for use in bio-marker 
studies. Collectively, these studies highlight that bio-specimen type, storage temperature and the 
period being stored all affect the analytical results (Saude & Sykes, 2007). 
Urine is one bio-specimen that is commonly and widely used as a non-invasive method to assess 
health, in both a clinical and epidemiological setting. It has advantages over blood as it enables the 
rapid development of assays, and is also very popular in metabolic investigations not only because of 
its non-invasive use, but also because of the complex metabolic nature of the fluid. Urine also gives 
the researcher the ability to collect multiple samples easily over a period of time (Saude & Sykes, 
2007), thus, for the purpose of this literature review, the focus will be on urine as a substrate to be 
used in research. 
For routine diagnostics and clinical purposes, the gold standard for urine collection, processing and 
analyses is within 24-hours. However, in addition, a few important factors needs to be considered 
include, collection procedures, the addition of preservatives, time taken between collection and 
storage, intermediate storage temperature, and number of freeze-thaw cycles (Remer, Montenegro-
Stellenbosch University  https://scholar.sun.ac.za
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Bethancourt & Shi, 2014). Therefore, studies of the long-term stability of urinary metabolites like 
creatinine, urea, osmolality, iodine, nitrogen, anions, cations, acid–base parameters, or organic acids 
following long-term storage are rare. 
Saude and Sykes (2007) highlighted the importance of proper sample handling and storage techniques 
for urine samples for future metabolomic studies as it ensures that the sample reflects the original 
metabolic state it was in before the testing of metabolites. Thus, different methods of sample 
preparation, such as centrifugation and filtration, the absence or presence of a preservative, as well 
as sample temperature storage were described because these parameters had significant effects on 
urine metabolites over time (Saude & Sykes, 2007).  
Urine, as mentioned before, is useful because it is a common and widely used non-invasive method 
to assess health, especially in a clinical setting. One example is pre-eclampsia (PE), which is a human-
specific pregnancy disorder of which the origins are unknown, and which serves as the disease model 
on which one of the study’s objectives was based (Buhimschi et al., 2014). If PE is left untreated, the 
pregnant women might experience progressive clinical deterioration, which can result in seizures 
(eclampsia), stroke, haemorrhage, kidney damage, liver failure and death. New-onset hypertension 
and proteinuria after 20 weeks of pregnancy is the key presentation of the PE syndrome. (Buhimschi 
et al., 2014). 
Both hypertension and urine proteinuria are used as a diagnostic gold standard to predict PE, however 
these diagnostic measurements are compromised when the mother has other predisposing conditions, 
for example, chronic hypertension (crHTN) (Buhimschi et al., 2014). Thus, there is a need to explore 
other urine bio-markers as potential diagnostic and or prognostic markers. But, if urine bio-markers 
are going to be considered as potential bio-markers then the stability of these metabolites needs to be 
considered when studying them, especially after storing them for long periods of time. 
Altogether, PE, the bio-banking aspect which includes sample processing and handling, processing 
and storage conditions, as well as urine as an alternative non-invasive bio-specimen provide the 
context for subsequent discussions. 
1.2. Fit for purpose: The importance of bio-specimen integrity 
In the era of omics and bio-marker validation studies, the need for large cohorts of good quality bio-
specimens is essential. In the past, researchers used to store samples with little consistency and 
forethought. Today, there is a collective effort to collect, store and distribute bio-specimens for 
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research and diagnostic purposes in a standardised and aligned manner. While storing samples is not 
new, the science of bio-banking and infrastructure, such as biobanks, have gained much attention 
lately as this complex science brings together multiple biological and social sciences and legislative 
disciplines. There are different types of bio-banks depending on where they are established, their size 
and range of bio-specimens collected. Bio-banks can either be based in an academic setting, hospitals, 
pharmaceutical or bio-technological companies or stand-alone organisations and there are bio-banks 
with specific focuses on what should be stored, i.e. tissue, population, twin or disease-specific bio-
banks. Maintaining bio-specimen quality is critical for a bio-bank as it will influence downstream 
analytical applications. Thus any variable that might be introduced during processes from collection 
through to bio-specimen transportation, processing, storage and analysis could contribute to bio-
specimen integrity and lead to distorted results if the bio-specimen is of bad or low quality (Hubel, 
Spindler & Skubitz, 2014).  
Most bio-banks, whether small or large, should have a quality assurance and risk management plan 
in place to ensure the viability of the bio-specimens and to maintain bio-specimen integrity through 
facility and equipment monitoring and maintenance following best practices and guidelines. This is 
essential especially during continuous power failures, which happen quite frequently in developing 
countries and affect the stability of the bio-specimens. In addition, most bio-banks use a laboratory 
information management system (LIMS) to categorise, organise, track and manage storage of bio-
specimens. 
In summary, bio-banks are essential for future bio-marker discovery and validation studies as they 
can provide access to high-quality bio-specimens with associated clinical data with high statistical 
reliability and would also ensure strict application of standardised protocols and QC, and address the 
effects of pre-analytical and storage variables. 
1.3. Infrastructure for bio-marker research 
As new technologies develop over time, it becomes increasingly important to ensure that various 
samples are collected, handled correctly, and stored according to standard operating procedures 
(SOPs) in order to be fit for purpose, especially since the ideal sample type and volume for biomarker 
studies and research is unknown (Swanepoel, Snyders & Grewal, 2015). 
The effect of storage conditions on the stability of bio-markers has been studied using various 
components such as purified nucleic acids, fluid bio-specimens such as serum, plasma, urine, cerebral 
spinal fluid and many more.  
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In pharmaceutical development, bio-markers have become important tools, serving as predisposition, 
predictive, prognostic and diagnostics companions to novel therapies which “aid in patient selection, 
treatment monitoring, adverse event risk assessment, and the extension of indications for established 
drugs” (Nolen et al., 2013). 
There are millions of bio-specimens currently stored around the world in bio-banks or as collections 
in academic settings containing bio-specimens that could be used for bio-marker validation studies. 
Since the storage conditions and processing conditions affect the suitability of these specimens for 
use in downstream processing, if not stored and processed according to standardised and aligned 
protocols, this could lead to uncertainty in the validity of the bio-marker studies and, subsequently, 
uncertainty in the interpretation of these studies.  
The observation by  Baker (2012) that “Our knowledge of the factors that impact a bio-specimen has 
not kept up, nor has the education of the users about how fragile a bio-specimen is” is crucial as we 
are constantly discovering new factors that influence samples and their stability. 
There have been many studies focused on long-term storage of bio-specimens for use in bio-marker 
studies. From these studies, it is evident that bio-specimen type, storage temperature and the period 
of storage, all affect the analytical results after storage. For example, Kluger et al. (2011 demonstrated 
a 15% increase in the concentration of two, stored, serum cancer markers following a 10-year period. 
In another study by Kisand et al. (2010), a dramatic decrease in the vascular endothelial growth factor 
(VEGF) was observed after it was frozen and thawed repeatedly at either -20 oC  or  -75 oC. Similarly, 
another study by Rouy et al. (2005) showed that the matrix metalloproteinase-9 (MMP-9), a 
biomarker for cardiovascular risk detection in clinical studies, degraded over time even when stored 
at -80 oC. Interestingly, during low temperature storage, some bio-marker analytes would increase in 
concentration over time. For example, Männistö et al. (2007) showed that thyrotropin (TPO), thyroid 
hormones (TSH, fT4, fT3), and thyroid auto-antibody (Ab) concentrations (TPO-Ab, TG-Ab) in 
human serum increased in concentration when stored for 23 years at -25 oC. In a similar study, it was 
shown that thyroid stimulating hormone (TSH) decreased and free triiodothyronine (fT3) and free 
thyroxine (fT4) concentrations increased when stored at -80 oC storage for 8 to 11 years (Hillebrand, 
Heijboer & Endert, 2017). Thus the literature highlights that sample type, storage temperature, 
duration and how a bio-specimen is processed all affect the stability of the analytes that are examined. 
Which analyte is going to be studied also plays a role as certain analytes are more stable than others. 
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1.4. Urine as a bio-specimen for diagnostic purposes 
The analysis of urine for any kind of diagnostic purpose dates well back to ancient times. Since then, 
urine and certain elements in the urine were used to diagnose renal diseases (Sharda et al., 2014) 
On average, urine contains up to 150mg/day of proteins and pathological proteinuria (>300mg/day), 
and how this occurs is divided into three categories (Figure 1.1 below). Firstly, Glomerula proteinuria 
(Glomerula disease) is the increase in the permeability of the glomerular capillary wall to macro-
molecules, especially albumin. Secondly, Tubular proteinuria (Tubulointerstitium disease) is when 
there is reduced re-absorption of proteins, normally present in glomerular filtrate. Thirdly, overload 
proteinuria is the result of an excess or overload of low-molecular-weight proteins. These proteins 
are normally re-absorbed by the proximal tubules (Barratt & Topham, 2007).  
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Figure 1-1: Kidney and its structural and functional components.  
Extracted from (Julian et al., 2009). Each human kidney (left top) contains ~1,000,000 functional units or nephrons 
(middle, top) that span the two regions of the kidney: cortex and medulla. Each nephron is composed of a filtration structure 
(glomerulus) and a downstream tubule comprised of 11 functional segments. An afferent arteriole delivers blood to the 
encapsulated glomerulus (right, top) where it enters the capillary network, undergoes ultra-filtration and its residual volume 
exits by the efferent arteriole to return to the systemic circulation. The ultra-filtrate enters the proximal tubule (PT) as the 
primary urine and is progressively modified as it flows through the remaining segments of the tubule. Glomeruli are 
located in the cortex, while the tubular portions of the nephrons span the cortex and medulla. This structural feature creates 
the necessary concentration gradients for extraction of salts, water and various compounds from the urine in the tubular 
lumens. Endothelial cell (E) line the capillaries and contain openings (fenestrae) that permit water, salts, and small proteins 
and low-molecular-weight compounds to filter across the glomerular basement membrane (GBM); arrows in the enlarged 
inset on the right-hand side depict the flow of ultrafiltrate). 
Preferable, urine protein concentrations are collected and analysed using the 24-hour gold standard, 
and are expressed as mg or g. On the other hand, in the untimed urine, spot collection method, the 
protein concentration is expressed as a ratio to compensate for variability of the urine volume and 
concentration between spots (Bertholf, 2014).  
Urine proteins and metabolites are useful in research studies of renal diseases, but the process of 
sample handling, processing and storage also has a significant effect on the quality and integrity of 
the sample (Ferraz et al., 2006). In urine, various metabolites can be assessed such as pH, citrate, uric 
acid, sulphate, sodium, potassium, cyclic adenosine monophosphate (AMP), calcium, magnesium, 
phosphorus, oxalate, ammonium and creatinine. Some important factors that can affect analysis 
include: if the urine is super-saturated with various solutes and contains bacteria if not collected 
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cleanly enough; if there is an error in sample handling then stone salt formation and precipitation can 
occur; also, oxidation of urinary ascorbic acid to oxalate can skew downstream analysis and 
subsequent results (Ferraz et al., 2006). Therefore, proper sample handling is of outmost importance. 
1.5. Urine metabolites and integrity 
Since molecular weight proteins are not being filtered and passed through to the kidney into the urine, 
metabolomic studies use this characteristic of molecular weight protein differences to identify and 
profile unique metabolic differences to associate with a specific pathophysiology (Saude & Sykes, 
2007). These profiles serve as urinary bio-markers which are used in practice to diagnose disease, 
thus a specific bio-marker can be used to diagnose a specific disease. One such example is PE, where 
the elevation of Adipsin (Complement Factor D) during pregnancy could be used as a bio-marker to 
test diagnostically for PE (Wang et al., 2014,;2016). Another example includes the presence of 
albumin which is an indicator of renal disease. Tracking the fluctuations in the metabolic changes of 
a metabolite in response to a disease provides information about the disease which can then be used 
as a bio-marker, resulting in possible strategies for care and prevention. These metabolic changes as 
shown in human urine studies, indicate changes that can be a result of age and diet, but also relate to 
variations in populations and between individuals over time (Saude & Sykes, 2007).  
The recent development of high-throughput, proteomic or metabolomic approaches has created new 
and expanded approaches to using bio-markers in urine for diagnostic purposes. This approach also 
enables the cataloguing of protein composition in fluids like plasma, serum, urine and saliva (Papale 
et al., 2007). Thus, urine has many metabolites available to explore as a diagnostic tool. As the 
integrity of these metabolites over time is unknown, these metabolites need to be preserved in long-
term storage at low temperatures. Therefore, prospective and longitudinal studies should pay extra 
attention to the collection and storage methodologies with regards to the stability of the metabolites 
in the urine because analysis cannot always occur immediately after collection. The stability of the 
metabolites in the urine is dependent on many factors and variables as mentioned earlier (Section 
1.3). Other factors to consider include collection procedures, the addition of preservatives, time taken 
between collection and storage, intermediate storage temperature , and number of freeze-thaw cycles, 
(Remer, Montenegro-Bethancourt & Shi, 2014). The study of the long-term stability of urinary 
metabolites lacks, in particular, the influence of preservatives in long-term storage. 
To date, there has been an increased reliance on the use of samples that have been stored for prolonged 
periods of time. One example involved patients with chronic kidney disease (CKD), where the impact 
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of sample handling, processing, duration of storage and other factors has become an area of significant 
interest (Liu et al., 2016). 
Saude and Sykes (2007) highlighted the importance of proper sample handling and storage techniques 
for urine samples to be used in future metabolomic studies because this ensures that the sample 
reflects the original metabolic state it was in before the testing of metabolites. Thus differences in 
sample preparation methods (centrifugation vs filtration), sample temperature storage (room 
temperature storage vs. ultra-low temperatures) are essential parameters that have significant effects 
on urine metabolites over time (Saude & Sykes, 2007). 
If urine metabolites are considered to be potential bio-markers, the stability of these metabolites must 
considered when studying them in urine. Remer et al. (2014) investigated the stability of urinary 
analytes with preservatives, after 12 to 15 years of storage at -22 oC. The analytes examined included: 
creatinine, urea, osmolality, iodine, nitrogen, chloride, phosphate, sulphate, sodium, potassium, 
calcium, magnesium, components of renal net acid excretion, pH, titratable acidity, ammonium, 
bicarbonate, and the organic acids citrate, uric acid, oxalate, and total (titrated) organic acids. This 
study by Remer et al. (2014) provided valuable information especially for future epidemiological 
studies, or intervention studies such as pre-eclampsia.   
Therefore, depending on the analyte that is being investigated, all the factors relating to laboratory 
techniques also need to be considered because the stability of the analyte depends on its metabolic 
structure as well as the matrix it is in, and the intra- and inter-individual, biological variabilities need 
to be remembered (Remer, Montenegro-Bethancourt & Shi, 2014).There have been several studies 
that evaluated certain urinary metabolites. Buyken et al. (2006) examined the stability of urinary C-
peptide (UCP) over 12 years. Likewise, Griefahn et al. (2001) investigated and showed that the 
concentration of 6-hydroxy melatonin sulphate (6-OHMS) remained stable over a 15-year period. 
Remer, Montenegro-Bethancourt and Shi (2014) noted and discussed a potential flaw in the literature 
where, for some research, no baseline measurements were taken before storage and after storage over 
a particular time. Liu et al. (2016) also discovered that the effect of long-term storage on bio-marker 
concentrations has not been studied well and that it is a really “methodological challenging problem 
to study”. Currently, there is no gold standard method by which to investigate the impact of storage 
time on bio-marker levels. Conducting repeated measurements from a single aliquot over the period 
of storage has been suggested but the study design can change and assays can change over time. 
Therefore, the methodology changes over time can invalidate the study (Liu et al., 2016). 
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Interestingly, urinary creatinine seems to be regarded as one of the most stable metabolites as it is not 
easily affected by short- or long-term storage conditions as indicated by Spierto et al. (1997) and 
Parekh et al. (2007). Urinary creatinine is stable from 30 days to 2.5 years at various temperatures 
ranging from -4 oC to -70 oC. 
Similarly, Remer, Montenegro-Bethancourt and Shi (2014) discovered and validated that urinary 
creatinine can also be stable at -22 oC for 15 years. 
On the other hand, oxalate is the exact opposite to creatinine as it is the least stable analyte (Ferraz et 
al., 2006). Oxalate is the most variable urinary metabolite and there are several factors to consider 
when investigating it, such as analytical methods and interactions with other molecules. For these 
types of metabolites, the addition of preservatives to urine samples in order to stabilise certain 
molecules or to reduce bacterial degradation of certain molecules becomes essential. Interestingly, 
some studies have found no differences in the concentration of urinary metabolites, such as calcium, 
magnesium, oxalate, with and without preservatives (Ferraz et al., 2006). By contrast, Yilmaz et al. 
(2008) discovered that calcium, magnesium, phosphate, and uric acid had a high level of stability 
when comparing measurement results of urine samples with and without preservatives.  
Remer, Montenegro-Bethancourt and Shi (2014) demonstrated that urine samples stored at -20 oC for 
up to 15 years have high stability for creatinine, urea, cations (sodium, potassium, calcium, and 
magnesium), ammonium, citrate, uric acid, iodine and nitrogen. Osmolality, anions (chloride, 
phosphate, sulphate), titratable acidity, bicarbonate, and total organic acids were found to be less 
stable or more prone to measurement errors (mostly small) over time. The study also highlighted that 
the addition of urine preservatives is not a requirement for long-term storage. 
However it should be noted that, the metabolites that were tested in Remer, Montenegro-Bethancourt 
and Shi, 2014 were tested at -20 oC, which raises the question of how they would have fared at -80 
oC. From the literature reviewed, there does not appear to be a collective study similar to study by 
Remer et al. (2014) but tested at -80 oC. 
However, in the study by Rist et al. (2013), urine aliquots were frozen either at −20 oC, on dry ice, at 
−80 oC or in liquid nitrogen and then stored at −20 oC, −80 oC or in liquid nitrogen vapour phase for 
1 to 5 weeks before nuclear magnetic resonance (NMR) analysis. Results showed spectral changes 
depending on the freezing process. Samples frozen on dry ice showed the largest deviations which 
were found to be based on pH differences caused by variations in CO2 concentrations that were 
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introduced by the freezing procedure. Therefore, the study recommended that urine samples should 
be frozen preferentially at -20 oC and then transferred to a lower temperature within one week. (Rist 
et al. (2013) also suggested that freezing procedures should be a part of all publication protocols or 
methodology.  
Alternatively, Papale et al. (2007) assessed urine stored with and without the addition of protease 
inhibitors and left at room temperature from 0 to 48 hours. The study found that, when storing urine 
at room temperature, a progressive degradation of proteins occurs, which could have been prevented 
if protease inhibitors were added within 2 hours from collection time. Papale et al. (2007) also 
demonstrated that the timing of urine collection during the day only had a minor impact on the protein 
profile, but had an influence on the peak intensity following (Surface-enhanced laser desorption or 
ionization used with time-of-flight mass spectrometry (SELDI-TOF–MS analysis). Freeze or thaw 
cycles were also investigated, and it was concluded that 5 freeze or thaw cycles did not affect the 
intensity of the peaks. The study also considered the inter-subject variability, which was fairly 
consistent, but between-subject variability was noted, especially between the two sexes (Papale et al., 
2007). 
1.6. The role and integrity of metabolites, albumin, creatinine, calcium, 
total protein and adipsin in urine   
Currently, the options for the measurement of proteins are either the total level of protein in the urine 
or the measurement of single proteins. Considering total protein, the daily excretion is about 
150mg/day. Ten mg of that 150mg is albumin (Barratt & Topham, 2007). Albumin is one of the 
urinary proteins that is measured to determine renal function because <100mg of albumin is filtered 
through the glomerulus per day when renal function is normal. Despite numerous proteins present in 
urine, albumin is the primary or first protein that will be observed thus making it a sensitive indicator 
for most renal diseases (Bertholf, 2014). Early renal disease is characterised by micro-albuminuria 
(30-300 mg/day) where the albumin is almost undetectable. Proteinuria or macro-albuminuria is 
characterised by >300mg/day. 
Creatinine is also used in the studies of kidney disease. Serum creatinine (SCr), concentration in 
mg/dl, is used to estimate kidney function, screen for acute kidney injuries and also to determine 
disease progression. Urine creatinine (UCr), concentration in mg/dl, is also used to estimate kidney 
tubular function, determine disease progression, as well as accuracy of timed urine collection. As 
these measurements are key to diagnosing kidney disease, it is thus of utmost importance to 
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understand the different techniques and sample storage methods that affect the measurements of SCr 
and UCr. Askenazi et al. (2014) explored the effects of different methodologies, under different 
storage conditions, on SCr and UCr over time. It was observed that UCr measurements seem to vary 
according to methodology, whereas SCr was consistent; UCr declined over time, whereas SCr was 
stable over time (1 year) with no difference between UCr and SCr whether the sample was refrigerated 
or frozen (temperature did not make a difference) (Askenazi et al., 2014). Creatinine can also be 
tested using the protein/creatinine ratio in UCr. To test the ratio, either the spot method can be used, 
which requires the collection of urine and drying it out on paper in a spot or the 24-hour urine 
collection method, which is the gold standard. Creatinine is also used in PE when combined with 
adipsin. The ratio between adipsin and creatinine can be used to assess PE diagnostically (Wang et 
al., 2014; 2016). 
Calcium (Ca2+) is also an important metabolite in renal function and is used to diagnose hypercalciuria 
(elevated Ca2+ in the urine), a condition that indicates impairment of renal function, nephrocalcinosis 
(deposition of calcium salts in the renal parenchyma due to hyper-parathyroidism), and renal 
insufficiency (Ferraz et al., 2006). Calcium plays a role in many cellular processes such as hormone 
secretion, muscle contraction, nerve conduction, and activation or inactivation of many enzymes. It 
is mostly absorbed in the gut, with only 30% absorbed from food. Other factors affect the absorption, 
such as the amount consumed and age or life stage. The amount absorbed will decrease as the amount 
of intake is increased; which is why infants or young children require more calcium than older adults. 
In addition, in some cases, an increase in calcium supplements has implications such as an increase 
of gall and renal stones, increased incidence of myocardial infarction and various fibrotic conditions. 
Similar complications such as increased heart attacks have also been observed in the elderly who take 
calcium supplements for the treatment of osteoporosis (Samozai & Kulkarni, 2015). In addition, 
Samozai and Kulkarni (2015) also described the effects of calcium supplements on menopausal 
women and concluded that giving calcium supplements does not change the concentration in calcium 
serum levels but did increase the urine calcium levels significantly. The gold standard would be 24-
hour collections of urine but the random urine collections can also be used for calcium measurements 
and is expressed in relation to creatinine. The normal reference for the urine:creatinine ratio 
(mg/dL:mg/dL) is <0.14. Hypercalciuria occurs when the ratio is >0.20. Thus, if an elevation of 
calcium to >300mg/24hrs is observed, then it is indicative of an over-active parathyroid gland and is 
presented as hypercalciuria and hyperphosphaturia. However, only 1/3 of patients presenting with 
hyper-parathyroidism have normal urine calcium levels so calcium is not an ideal analyte for the 
measurement of parathyroidism. On the other hand, for pre-eclampsia, Imdad, Jabeen and Bhutta 
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(2011) discussed that many epidemiological and clinical studies have shown that there is an inversely 
proportional relationship between calcium uptake or supplementation and the development of 
hypertension during pregnancy. The effect of calcium supplementation varies according to baseline 
calcium intake and any pre-disposing factors. In their review of the literature, Imdad, Jabeen and 
Bhutta (2011) found that calcium supplementation was associated with a decrease in the risk of 
hypertension during pregnancy as well as pre-eclampsia, neonatal mortality, and pre-term birth.   
Adipsin (also known as Complement Factor D, c3 convertase activator) is a serine protease secreted 
in adipose tissue that is expressed at high levels. Therefore, Adipsin forms part of the alternative 
pathway (Figure 1-2) for complement activation. Adipsin or factor D (fD) catalyses the formation of 
a C3-cleaving enzyme by interacting with factor B (fB) and C3b. During pregnancy, the complement 
system has an increased activation which has been suggested to offset the suppression of the adaptive 
immunity during normal pregnancy. There have also been indications where some complement 
complexes and proteins are deposited into both normal and pre-eclamptic placentas with the latter 
having more being deposited. The adipose tissue is therefore an important factor in PE. Especially in 
the production of pro-inflammatory cytokines that are involved in many endocrine functions. It is 
also noted that women with PE have decreased levels of high-density lipoprotein cholesterol (HDL-
cholesterol) and increased levels of triglycerides and insulin levels. This relationship between PE and 
the complement activation pathway is important and measurements of complement activation 
products are shown to be increased in PE pregnancies in comparison with normal pregnancies 
(Poveda et al., 2016). In the role of metabolic control, glucose transport systems and adipocyte 
triglyceride synthesis are stimulated by Adipsin through an insulin-dependent mechanism. Therefore, 
studies have shown that Adipsin is increased in obesity and type 2 diabetes. This raises the question 
of how to diagnose PE in pregnant patients who are either obese or diabetic, or both. Thus, Adipsin 
plays a role in fat metabolism and glucose homeostasis. In their research, Wang et al. (2014; 2016) 
describe a relationship between Adipsin and creatinine. The relationship between Adipsin and 
creatinine, measured by using a rapid test and expressed as a ratio, was closely correlated to the 24-
hour urinary protein in patients with pre-eclampsia. The rapid test was then combined with the 
increased diastolic blood pressure levels (≥ 90 mm Hg) to diagnose PE. The sensitivity was 90.3% 
and the specificity reached 100.0% for pre-eclampsia diagnosis. 
From the above-mentioned studies for the different analytes, it is clear that protein, albumin, 
creatinine, calcium and Adipsin all play a role in PE and this makes each analyte an important bio-
marker in the study of PE. 
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Figure 1-2: The Alternative Complement Pathway.  
When a C3b fragment binds to a microbe, C3b changes shape which allows factor B (fB) to bind. This, in turn, allows 
Adipsin or factor D (fD) (referenced by * in the image) to bind to fB. This then cleaves fB to Ba and Bb. Bb will stay 
bound as C3(H2O)Bb(P) and Ba will become Ba on its own. C3 is the C3-convertase (C3 belongs to family of serine 
proteases and is necessary in innate immunity as a part of the complement system in the alternative pathway). 
1.7. Urine stability challenges related to infrastructure 
Urine metabolite stability is an important concern and there are standardised methods to ensure the 
stability of urine metabolites throughout handling and processing. Storing samples at the correct 
temperature is crucial to ensure urine metabolite stability. However, in practice, infrastructure 
challenges might influence the storage conditions that are considered. The decision also depends on 
the downstream applications for which the sample will be used and whether the required 
infrastructure is available or not. For example, one would use refrigeration (4oC or -20oC) as a short- 
term or temporary solution when high volumes of urine are submitted to a laboratory for processing, 
or long-term storage at -80 oC for analysis at a later stage depending on whether the infrastructure is 
in place. 
Froom et al. (2000) describes the use of refrigeration as a facility for overnight storage in order to 
complete all analysis without rushing which would introduce human error. In certain clinic settings, 
it can be quite difficult to ensure that samples arrive the same day as collection, which is why 
refrigeration is an important storage method as it partially stabilises the urine analytes for analysis 
* 
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the next day (Froom et al., 2000). It is also important to note that the degree of stability varies with 
the type of sample being used. 
1.8. Overview of PE 
PE is a human-specific pregnancy disorder of which the origins are unknown, and which serves as 
the disease model for this study. If PE is left untreated, pregnant women might experience progressive 
clinical deterioration which can result in seizures (eclampsia), stroke, haemorrhage, kidney damage, 
liver failure and death. New-onset hypertension and proteinuria after 20 weeks of pregnancy is the 
key symptom of PE syndrome. Table 1-1 below shows the diagnostic criteria and classification of 
hypertensive disorders during pregnancies (Williams, Pipkin & Fiona, 2011). Unfortunately, PE is 
not a predictable syndrome as its clinical presentation can be variable and the speed of progression 
can be slow or fast. It has been noted that altered concentrations of soluble fms-like tyrosine kinase 
1 (sFlt-1) and placental growth factor (PIGF) can be used to predict if PE will occur, before the onset 
of the clinical symptoms. Unfortunately, these predictive indicators do not monitor the exact 
occurrence of PE (Wang et al., 2014). Both hypertension and urine proteinuria are used as a diagnostic 
“gold standard” to predict PE but these diagnostic measurements are compromised when the mother 
has other predisposing conditions, for example, chronic hypertension (crHTN) (Buhimschi et al., 
2014). Hence the need to explore other urine bio-markers as potential diagnostic or prognostic 
markers. 
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Table 1-1: Diagnostic criteria and classification of hypertensive disorders of pregnancies. 
Taken from Williams, Pipkin and Fiona, 2011. 
Classification Diagnostic criteria 
Gestational hypertension Hypertension: blood pressure ≥ 140/90 mmHg after 20th week of 
pregnancy in a previously normotensive woman. 
Pre-eclampsia Hypertension: blood pressure of ≥ 140/90 mmHg after 20th week of 
pregnancy in a woman who was previously normotensive. 
Proteinuria: urinary excretion ≥ 300 mg/L or 500 mg/24 hours in the 
absence of urinary tract infection. 
Eclampsia Occurs in a woman with pre-eclampsia. Characterised by seizures 
not attributed to other causes. 
Super-imposed pre- 
eclampsia 
Chronic hypertension with development of proteinuria during 
pregnancy. 
Chronic hypertension Hypertension present before 20th week of pregnancy, persistent for 
more than 6 weeks postpartum, or both. 
1.9. Present Study 
For the present study, a PE-based cohort which forms part of the Calcium and Pre-eclampsia (CAP) 
study was evaluated for one of the objectives. The CAP study was a World Health Organisation 
(WHO) collaboration that formed part of the pre-eclampsia and eclampsia monitoring, prevention 
and treatment (PRE-EMPT) consortium and was made up of collected urine bio-specimens from 
Argentina, Zimbabwe and South Africa. It aimed to develop a rapid diagnostic test for PE in pregnant 
women because early identification of PE would decrease the likelihood of maternal and perinatal 
mortality and improve antenatal care, management and treatment. Therefore, the identification of 
potential bio-markers is of importance in PE, and urine, being a non-invasive bio-specimen has the 
potential to help predict PE as proteinuria in the urine can be detected and quantified. Therefore, the 
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present study was an explorative study that took existing data from the larger mother study to conduct 
a pilot study into the different factors influencing metabolite stability in long-term storage at -80oC. 
The aim of this study was to investigate the effect of long-term urine bio-banking on the stability of 
urine bio-markers in the diagnosis of pre-eclampsia by understanding the variety of storage conditions 
and their effect on bio-markers. 
To achieve the aim of this study, the objectives were: 
1) Conduct a pilot study to compare high-throughput vs. dipstick measurements of Creatinine, 
Total Protein and Calcium in urine aliquots from the PE based CAP cohort stored long-term 
at -80oC (henceforth shortened to “Objective 1: Dipsticks vs High-throughput”). 
2) Evaluate the Enzyme-linked immunosorbent assay (ELISA) validation of Adipsin or 
Complement Factor D measurements for long-term stored urine (henceforth shortened to 
“Objective 2: Adipsin”). 
3) Investigate the pre-analytic effect of pre- and post-storage conditions and processing of 
samples by measuring Total Protein, Urea, Albumin, Calcium and Creatinine after a set period 
of storage at -80oC (henceforth shortened to “Objective 3: Storage”).  
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Chapter 2  
Methodology 
2.1 Study Setting and Background 
This explorative study was conducted in association with the National Health Laboratory (NHLS) in 
conjunction with Stellenbosch University (SU) Biobank, shortened to NSB, within the Division of 
Haematology based at Tygerberg Hospital and forms part of a larger study which was approved by 
the Health Research Ethics Committee of the Faculty of Medicine and Health Sciences of the 
University of Stellenbosch (Biobank ethics Ref number: N15/10/119 and University of 
Witwatersrand HREC Clearance Certificate: M10977; University of Cape Town: 457/2010; WHO 
trial reference number: A65750). NSB is a registered bio-bank/repository, and is affiliated with the 
NHLS and SU. NSB is also a partner/member of The Human Heredity and Health in Africa 
consortium (H3Africa), Bridging Biobanking and Biomedical Research across Europe and Africa 
Consortium (B3Africa), The Biobank and Cohort Building Network (BCNET), Global Emerging 
Pathogens Treatment Consortium (GET) and various other consortia. This specific study had 3 main 
objectives where three different modus operandi were employed. In this chapter, the target population 
of all three objectives has been discussed followed by discussion of separate methodologies in terms 
of sample collection, processing, and data analysis. 
2.2 Cohort population background and pre-analytical variables and 
storage conditions 
For objective 1, a PE-based cohort which formed part of the CAP study was evaluated. The CAP 
study is a WHO collaborative that forms part of the PRE-EMPT consortium and is made up of urine 
bio-specimens collected from Argentina, Zimbabwe and South Africa. The South African urine 
samples were collected since 2013 and stored onsite at -80oC at Groote Schuur Hospital (Cape Town, 
Western Cape), Chris Hani Baragwanath Hospital (Johannesburg, Gauteng), Fort Hare (East London, 
Eastern Cape) and Cecilia Makiwane Hospital (East London, Eastern Cape) before it was 
consolidated and stored at NSB, a central repository facility for the CAP study in 2016. These urine 
samples were acquired from pre-pregnant, pregnant and post-pregnant women (labelled ADM, PPV, 
DPV8, DPV20, DPV32, POST-P and PE) as shown in Table 2-1. 
Stellenbosch University  https://scholar.sun.ac.za
18 
2.2.1. Pre-analytical variables and storage conditions at collection sites 
The WHO CAP SOP required samples to be stored immediately at -80oC following collection; 
however, in cases where ultra-low temperature storage was not available, urine samples were allowed 
to be stored on ice for 24 hours or at -2 to -8oC for 8 days or at -20oC for 3-6 months before freezing 
at -80oC (Appendix A). As samples were collected in busy, routine clinics, it is not known what the 
time frames and the short-term storage temperatures were after collections and whether these pre-
analytical variables were captured. In addition, the prescribed SOP for collection of urine samples 
did not follow the gold standard method, which requires centrifugation of urine at low speed of 1600 
x g /2500 rpm for 15 minutes and aliquoting the supernatant for long term storage at -80oC. 
Table 2-1: Labelling format of the weeks. 
Abbreviation Full 
PPV Pre-Pregnancy 
ADM Admission 
DPV8 Week 8 of the pregnancy 
DPV20 Week 20 of the pregnancy 
DPV32 Week 32 of the pregnancy 
POST-P Post-Partum/Pregnancy 
PE Pre-eclampsia 
2.2.2. Sample shipment to NSB central biorepository 
Samples were shipped in batches from various sites on dry ice and packed according to NSB policies, 
guidelines and SOPs (Appendix A and B) as well as IATA regulations (IATA, 2018). The courier 
company, Marken, collected the Marken’s BioSystem Boxes (BIOIII) filled with dry-iced from the 
sites at specific times for overnight delivery (Figure 2-1). Upon delivery, the samples were 
immediately transferred to freezers at -80oC (Snijders Scientific, Tilburg, Netherlands). In order to 
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standardise and align procedures, NSB was given the responsibility to verify or cross-check the 
samples against the CAP compiled database, re-organise, re-label with both 1D and 2D unique 
barcodes and re-store and capture storage location sites because each site had its own guidelines for 
sample collection and data compilation. All data were captured using Excel. 
2.2.3. NSB sample verification, relabelling and re-storage 
In 2016, it was requested that the urine bio-specimens be moved to NSB in Cape Town in order to 
relabel, re-organise and re-check them against the CAP compiled database. A number of issues were 
observed in the collections, of which labelling and overfilled tubes were major concerns. In order to 
standardise and align procedures, urine bio-specimens were re-labelled with both 1D and 2D unique 
barcodes, re-organised and re-checked (Figure 2-1 and 2-2). This resulted in improved ease of search 
and access to bio-specimens via a LIMS as well as an excellent cohort that would be of benefit to the 
wider PE research community. Figure 2-1 and 2-2 below show some of the issues and solutions. 
The stored cohort were supposed to be used in a larger study which aims to determine the value of 
the Protein/Creatinine (Pr-Cr) strip for urinalysis developed by Life Assay Company in detection of 
early pre-eclampsia in pregnant women. The objectives were: (1) Value of the Pr-Cr strip vs standard 
protein only strip in identification of women with pre-eclampsia; (2) Compare the strip with a 
standard biochemical Pr-Cr assay and a more expensive Pr-Cr strip (Siemens) and with pregnancy 
outcome; (3) Further usefulness of the strip will be done by comparing readings by midwives with 
laboratory assay of protein and creatinine and the more expensive strip by Siemens.  
A small pilot was performed first to measure the same analytes to determine whether the integrity of 
the samples was still intact and whether optimal results would be obtained despite the lack of 
knowledge regarding pre-variables prior to arrival at NSB.  
Stellenbosch University  https://scholar.sun.ac.za
20 
 
 
A 
 
 
B 
Figure 2-1: Shipments and Relabelling.  
A indicates the arrival of the samples. They were packed according to IATA guidelines into a certified Marken box with 
dry ice for transport. B indicates the before and after labelling of tubes. Paper-based or permanent marker labels were 
replaced with both a 1D and 2D cryo-protecting barcode to allow for easy scanning and tracking. 
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Figure 2-2: Re-organisation and storage.  
Before and after photographs of the boxes showing open spaces. Following re-organisation, the 2ml tubes were re-
organised from left to right (1-10) and placed left to right on each row (A-J) in order to use storage space appropriately 
and assign storage space location. 
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2.3 Target population and sample collection 
2.3.1 Objective 1: Dipsticks vs high-throughput 
For this part of the study (Objective 1), approximately 70 frozen urine samples were accessed from 
NSB per week. However, for this particular study, only 68 aliquots from Week 32 were used for the 
pilot and the subsequent data analysis. The samples were thawed overnight in the fridge at 4oC before 
being processed the next morning. 
Processing and analysis of the samples were two-fold: firstly, samples were aliquoted into the correct 
prescribed tubes for the diagnostic, clinical, high-throughput measurements and subsequently 
submitted to the Division of Chemical Pathology, an ISO 15189 accredited NHLS diagnostic 
laboratory at Tygerberg Hospital, to measure creatinine, calcium and total protein (See Section 2.4.1.2 
for further details on test principles). High-throughput measurements for total protein were made via 
the automated system (Roche Cobas 6000 analyser, Risch-Rotkreuz, Switzerland) as well as the 
Siemens (protein) dipstick (Multistix 5, Siemens Healthcare Diagnostics Inc, Tarrytown, NY, USA), 
which is the gold standard used currently in South African clinics. In parallel, the same set of samples 
were used to test the newly developed LifeAssay dipstick which can measure both creatinine and 
protein.  
2.3.2 Objective 2: Adipsin 
For Objective 2, a small sub-set of the frozen urine samples from 14 patients over the weeks (ADM, 
DPV8, DPV20 and DPV32) were accessed from NSB. These samples were used for the analyte 
measurements described above as well as for the Adipsin validation study following overnight 
thawing at 4oC. The Adipsin or Complement Factor D (CFD) measurement were determined via the 
Enzyme-linked Immunosorbent Assay Kit for CFD (Cloud-Clone Corp, Houston, USA) according to 
the manufacturer’s protocol (See Section 2.4.2 for more details). The plates were then read on the 
ELISA plate reader (Bio-Rad, California, USA). 
2.3.3 Objective 3: Storage 
For Objective 3, fresh urine samples were acquired from 20 consenting volunteers (See Appendix C) 
using a 50 ml urine collection container (Tygerberg Hospital) according to the international best 
practices guidelines on urine sample collection (Appendix A). Subsequently, urine samples were 
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processed following the gold standard or according the workflow outlined in Section 2.4.3. The 
amount filled in the container was aliquoted equally over 12 urine tubes for storage. 
2.4 Analyte measurements  
The aim of the larger study was to compare the LifeAssay Dipstick with the Siemens gold standard 
Dipstick but also with high-throughput, clinical measurements obtained in an accredited, diagnostic 
laboratory’s high-throughput instruments. The principles for each methodology employed for analyte 
measurement have been discussed in the following sections. 
2.4.1 Objective 1: Dipsticks vs high-throughput 
2.4.1.1. The newly developed LifeAssay vs Siemens Dipsticks 
Both the Siemens Dipstick (performed as part of accredited, clinical, high-throughput) and LifeAssay 
Dipstick (performed in-house) were used to measure total protein, and both protein and creatinine in 
the case of the LifeAssay Dipstick. Prior to measurement, the thawed urine samples were gently 
mixed to ensure even distribution of particles. Following the mixing of urine, a small aliquot (1-2 
drops) was dropped onto each section square of both dipsticks (LifeAssay and Siemens). After 60 
seconds, both dipsticks were softly blotted onto a paper towel. Subsequently, a visual interpretation 
was done and a photograph was taken of the dipstick to ensure the colour change was recorded for 
each sample. See Figure 2-3 below. 
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Figure 2-3: Representative images and visual interpretation of both the LifeAssay PrCr Dipstick (A) 
and the Siemens Protein Dipstick (B).  
The yellow to green colours for the LifeAssay represents the presence and absence of total protein whereas white to 
brownish pink represents the presence or absence of creatinine. 
2.4.1.2. High-throughput Clinical Lab Automated system 
Clinical measurements for each analyte were taken according to validated SOPs (Appendix D, E and 
F). 
For these clinical measurements, the thawed urine samples were mixed vigorously to ensure that 
precipitated calcium was dissolved adequately after long-term storage (See Appendix A). Precipitated 
Calcium would have skewed subsequent clinical Calcium measurements if urine samples were not 
properly mixed. Between 200ul to 1ml, depending on availability, were aliquoted into a blue-top tube 
provided by the Chemical Pathology diagnostic laboratory. Once aliquoted, the urine was analysed, 
and Creatinine, Calcium and Total Protein were measured using the Roche Cobas 6000 analyser 
(Roche, Risch-Rotkreuz, Switzerland) according to the laboratory’s validated protocol. For the sake 
of context, the principle underlying each analyte measurement has been discussed briefly in the sub-
sections below. 
2.4.1.2.1.  Clinical Creatinine measurement 
An in vitro test for the quantitative determination of creatinine concentration in human serum, plasma 
and urine specimens carried out using the Roche/Hitachi Cobas C systems. This enzymatic method 
is based on the conversion of creatinine, with the aid of creatininase, creatinase, and sarcosine 
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oxidase, to glycine, formaldehyde and hydrogen peroxide. Catalysed by peroxidase, the liberated 
hydrogen peroxide reacts with 4-aminophenazone and (HTIBa) to form a quinone imine chromogen. 
The colour intensity of the quinone imine chromogen formed is directly proportional to the creatinine 
concentration in the reaction mixture as shown in Figure 2-4 (See Appendix D for more details on 
the test procedure). 
 
Figure 2-4: Test Principle for in vitro creatinine quantification.  
2.4.1.2.2. Clinical Calcium measurements 
An in vitro test for the quantitative determination of Calcium in human serum, plasma and urine was 
carried out using the Roche/Hitachi Cobas C systems. In this assay, Calcium ions reacted with 
5-nitro-5’-methyl-BAPTA (NM-BAPTA) under alkaline conditions to form a complex. This complex 
reacts in the second step with EDTA. The subsequent changes in absorbance were directly 
proportional to the Calcium concentration and was measured photometrically as shown in Figure 2-
5 (See Appendix E for more details on the test procedure). 
 
Figure 2-5: Test Principle for in vitro calcium quantification.  
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2.4.1.2.3. Clinical Total Protein measurements 
An in vitro test for the quantitative determination of protein in human urine and cerebrospinal fluid 
was performed using the Roche/Hitachi Cobas C systems. An automated Turbidimetric method was 
employed. The sample was pre-incubated in an alkaline solution containing EDTA, which denatured 
the protein and eliminated interference from magnesium ions. Benzethonium Chloride was then 
added, producing turbidity as shown in Figure 2-6 (See Appendix F). 
 
Figure 2-6: Test Principle of the Turbidimetric method for the quantitative protein in vitro 
test. 
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2.4.2 Objective 2: Adipsin 
The commercial Enzyme-linked Immunosorbent Assay Kit for Complement Factor D (CFD) (Cloud-
Clone Corp, Houston, USA) was used to measure Adipsin within the subset of 14urine samples 
chosen according to the manufacturer’s protocol (Appendix G). The kit itself is a sandwich enzyme 
immune-assay that is used for the in vitro quantitative measurement of Adipsin or CFD in human 
serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids 
based on the Sandwich ELISA Concept (Figure 2-7). The microplate provided was pre-coated with 
an antibody specific to Adipsin or CFD. Standards and samples (100ul) were added, with the sample 
added in triplicate to the appropriate microplate wells with a biotin-conjugated antibody specific to 
CFD (Figure 2-8). Next, Avidin conjugated to Horseradish Peroxidase (HRP) (Detection Reagent B) 
was added to each microplate well and incubated. Subsequently, TMB substrate solution was added, 
and only those wells that contained CFD, biotin-conjugated antibody and enzyme-conjugated Avidin 
exhibited a change in colour. This enzyme-substrate reaction was terminated by the addition of 
sulphuric acid solution and the colour change was measured spectrophotometrically at a wavelength 
of 450nm ± 10nm on an ELISA plate reader (Bio-Rad, California, USA). The concentration of CFD 
in the samples was then determined by comparing the optical density (OD) of the samples to the 
standard curve. 
 
Figure 2-7: The Sandwich ELISA Concept.  
The base/plate is coated with a capture antibody; following the addition of the test sample, the target antigen present will 
bind to the capture antibody. Subsequently, a second antibody is added, and binds to the antigen which creates a sandwich 
concept. Lastly an enzyme-labelled antibody is added, which binds to the second antibody. Following a specific substrate 
addition, enzyme conservation results in the measurement of a detectable form.  
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Figure 2-8: Summary flow diagram for the ELISA methodology. 
2.4.3 Objective 3: Storage  
Twenty participants provided urine in a 50ml container, which was subsequently aliquoted into 12 
urine tubese. Therefore, there were 240 tubes after aliquoting. The 240 urine collection tubes were 
grouped into 4 groups in triplicate to account for human error and sample variation. Thus, each group 
had 60 tubes (in triplicate) as shown in Figure 2-9. For group 1, which served as the baseline and 
followed the gold standard, triplet urine tubes were centrifuged at 2500rpm for 10 minutes and then 
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immediately stored at -80oC. Group 2 were centrifuged at 2500rpm for 10 minutes and then stored at 
4oC for 48 hours and subsequently stored at -80oC. Group 3 were centrifuged at 2500rpm for 10 
minutes and then stored at room temperature (25oC) for 48 hours and subsequently stored at -80oC. 
Group 4 was stored only at -80oC without centrifugation. Each tube was then thawed after 3 months, 
according to guidelines (Appendix A). After thawing, each tube was transferred into a blue-top tube 
provided by the Chemical Pathology diagnostic laboratory. Once aliquoted, the urine was analysed, 
and Albumin, Creatinine, Calcium, Urea and Total Protein were measured using the Roche Cobas 
6000 analyser (Roche, Risch-Rotkreuz, Switzerland) according to the laboratory’s validated protocol 
(Appendices D, E, F, and H). 
 
Figure 2-9: Flow diagram of the different types of processing being tested in comparison with the gold 
standard*.  
N = 60 per group. Total = 240 tubes.  
  
* 
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2.5 Data Analysis 
Objectives 1 and 3 were achieved in conjunction with a statistician from the Statistics Department, 
Stellenbosch University. Objective 2 was achieved independently. 
2.5.1 Objective 1: Dipsticks vs high-throughput 
Agreement analysis was performed between the laboratory high-throughput and the dipsticks, using 
the concordance correlation co-efficient (Lin’s coefficient). The concordance correlation co-efficient 
measures both precision and accuracy to determine how far the observed data deviate from the line 
of perfect concordance (y=0). Firstly, the Siemens dipstick results were compared with the Life Assay 
results, then both the Siemens and Life Assay results were compared respectively with the clinical 
high-throughput result. 
Trend analysis was also calculated for each analyte (Calcium, Total Protein and Creatinine), for both 
the dipsticks and the high-throughput measurements, at each time point (ADM-1, DPV8-8, DPV20-
20 and DPV32-32). In addition, the mean value and the corresponding 95% confidence interval were 
also calculated. Variance-weighted least-squares regression was used to test whether the linear trend 
was significant or not and to observe whether there was an increase over the weeks for each dipstick 
and laboratory result. Goodness-of-fit chi2 was used to test whether the single population fitted the 
hypothesised distribution. Lastly, the model fit chi2 was used to compare the weeks to each other 
(across categories). 
2.5.2 Objective 2: Adipsin 
For the ELISA-based results, the analysis was computed using Excel 2013 to create the standard 
curve for both the original and adjusted results, to acquire the R2 value and equation to calculate the 
%CV values. Two measures of the Co-efficient of Variability (CV) should be reported: the Inter-
Assay CV (plate-to-plate consistency) and the Intra-Assay CV (an average value calculated from the 
individual CVs) in order to express the precision, or repeatability. CV is a dimensionless number 
defined as the standard deviation of a set of measurements divided by the mean of the set. 
2.5.3 Objective 3: Storage 
Wilcoxon Signed-Rank Test was used for objective 3 Each group (Group 2, 3 & 4) were compared 
to the reference group (Group 1) using an average of the 20 patients for each analyte. The Wilcoxon 
Signed-Rank Test will indicate how different the groups’ values are to the reference. The data will be 
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a matched data set (measurements were from the same individuals but under different conditions). 
Due to the small sample size, it will be assumed that the dataset will be skewed, however the 
Wilcoxon Sign-Rank Test used to account for the small sample size. Excel 2013 was then used to 
present the data in graphical format.  
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Chapter 3 
Results 
The aim of this study was to: investigate the role of long-term urine bio-banking on the stability of 
urine bio-markers in the diagnosis of pre-eclampsia by understanding the variety of storage conditions 
and their effects on bio-markers.  
Therefore, to achieve the aim of this study, the objectives were: 
1) Conduct a pilot study to compare high-throughput vs dipstick measurements of Creatinine,
Total Protein and Calcium in urine aliquots from the PE based CAP cohort stored long-term
at -80oC (shortened to “Objective 1: Dipsticks vs High-throughput”).
2) Evaluate the ELISA validation of Adipsin or Complement Factor D measurements for long-
term stored urine (shortened to “Objective 2: Adipsin”).
3) Investigate the pre-analytic effect of pre- and post-storage conditions and processing of
samples by measuring Total Protein, Urea, Albumin, Calcium and Creatinine after a set period
of storage at -80oC (shortened to “Objective 3: Storage”).
Thus, the results obtained have been presented in the above order. 
3.1 Objective 1: Dipsticks vs high-throughput 
3.1.1 Clinical high-throughput measurements verses dipsticks measurements 
comparisons – Concordance correlation co-efficient analysis 
To compare the agreement between the laboratory high-throughput measurements with the dipsticks 
measurements, the concordance correlation co-efficient analysis (Lin’s co-efficient) was used to 
measure both precision and accuracy by determining how far the observed data deviated from the line 
of perfect concordance.   
Since the purpose was to assess the dipsticks compared with the high-throughput measurements, only 
the last of the cohort week (week 32) was selected for the agreement analysis. For agreement analysis 
using the protein measurements, the two dipsticks (Siemens vs LifeAssay) were compared with each 
other before the respective dipsticks was compared with the clinical high-throughput measurements. 
As creatinine was only measureable on the LifeAssay dipstick and not the Siemens dipstick, the 
LifeAssay results were compared with the clinical high-throughput measurements. 
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Data analysis was performed on both raw data and log transformed data where required, thus the data 
has been presented in that order. 
3.1.1.1 Siemens Protein Dipstick (SP) vs Life Assay Protein Dipstick (DP) 
For this analysis, the Lin’s co-efficient graph generated (Figure 3-1) shows that some data points lay 
on the y=0 line, which indicates that the data set was correlating between the two dipsticks for the 
protein results (accuracy). The average agreement mean was 1.818. A data point outside of the 95% 
limits was also observed, which reduced the co-efficient value from 1. The rho_co-ef or concordance 
correlation co-efficient was 0.920 with a 95% confidence interval (0.879 to 0.960), p-value = 0.000, 
suggesting substantial agreement between the two dipsticks. The p-value obtained indicated that this 
observation was statistically significant. The slope was 0.996 with 1 being considered the ideal slope 
and the intercept was 1.838 with 0 being considered the ideal intercept. Unfortunately, due to some 
values being 0, log transformation couldn’t be performed on this data set. 
 
Figure 3-1: Concordance correlation co-efficient of Siemens protein dipstick (Sprotein) vs LifeAssay 
protein dipstick (Dprotein).  
Substantial concordance was observed between the two dipsticks. Rho_Co-ef. = 0.920 (95%CI, 0.879 to 0.960), p-value 
= 0.000. 
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3.1.1.2 Siemens Protein Dipstick (SP) vs Laboratory High-throughput Protein (LP) 
For this analysis, the Lin’s co-efficient graph in Figure 3-2A below shows that the majority of the 
data points lay on the y=0 line. However, an observed data point was outside the 95% limits which 
reduced the co-efficient value from 1. The average agreement mean was -137.509.  The rho_co-ef or 
concordance correlation co-efficient was -0.002 with a 95% confidence interval (-0.008-0.004), p-
value = 0.564, suggesting poor agreement between the Siemens dipsticks and the clinical high-
throughput protein measurements. The p-value obtained indicates that this observation was 
statistically non-significant. The slope was -0.012 with 1 being considered the ideal slope and the 
intercepts was 7.852 with 0 being considered the ideal intercept. 
It was noted that the dipstick and the clinical high-throughput measurement ranges differed 
significantly from very low to very high between the two measurements. The minimum to maximum 
range for the Siemen’s protein dipstick was 0-30 whereas the clinical high-throughput measurements 
minimum to maximum range was from 0-6800. Owing to these different measurement ranges, the 
data set was log transformed in order to normalise it to a specific range. This would make highly 
skewed data, as in this case, less skewed as a result of measurement range differences. 
Thus, from this Lin’s co-efficient plot, Figure 3-2B below shows that all data points lay between the 
95% limits. The average agreement mean was -0.288. The rho_co-ef or concordance correlation co-
efficient was 0.076 with a 95% confidence interval (-0.364 to -0.516), p-value = 0.735, suggesting 
poor agreement between the Siemen’s dipsticks and the clinical high-throughput protein 
measurements. The p-value obtained indicated that this observation was statistically non-significant. 
The slope was 1.018 with 1 being considered the ideal slope and the intercept was -0.343 with 0 being 
considered the ideal intercept.  
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Figure 3-2: A: Concordance correlation co-efficient of Siemens protein dipstick (Sprotein) vs clinical 
high-throughput protein measurements (Lprotein). B: Concordance correlation co-efficient of 
Siemens protein dipstick (Sprotein) vs clinical high-throughput protein measurements (Lprotein) in 
log-transformed form.  
A - Poor concordance was observed between the Siemens dipstick and the clinical high-throughput measurements. 
Rho_Co-ef. = -0.002 (95% CI, -0.008 to 0.004), p-value = 0.564. B - Poor concordance was observed between the 
Siemens dipstick and the clinical high-throughput log transformed measurements. Rho_Co-ef. = -0.076 (95% CI, -0.364 
to 0.516), p-value = 0.735. 
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3.1.1.3 Life Assay Protein Dipstick (DP) vs Laboratory High-throughput Protein (LP) 
The Lin’s co-efficient graph for the LifeAssay Dipstick compared with the clinical high-throughput 
measurements showed that some data points lay on the y=0 line (Figure 3-3A below).  The average 
agreement mean observed was -24.985 which is not close to 0. An observed extreme data point was 
also outside the 95% limits which reduced the co-efficient value from 1. The rho_co-ef or 
concordance correlation co-efficient was 0.008 with a 95% confidence interval (-0.014 to 0.031), p-
value = 0.456, suggesting poor agreement between the Life Assays dipsticks and the clinical high-
throughput protein measurements. The p-value obtained indicate that this observation was statistically 
non-significant. The slope was 0.047 with 1 being considered the ideal slope and the intercept was 
6.014 with 0 being considered the ideal intercept. 
Owing to the extreme outlier value, the data set was adjusted by removing this outlier and the data 
were re-analysed to see how this influenced the results. As demonstrated before, the Lin’s co-efficient 
graph in Figure 3-3B below showed that some data points lay on the y=0 line. The average agreement 
mean observed was -24.985 which is not close to 0. With the removal of the extreme data point a 
rho_coef or concordance correlation coefficient of 0.533 with a 95% confidence interval (0.0475 to 
0.590), p-value = 0.000 was observed. Despite the removal of the outlier, the results still suggest poor 
agreement between the Life Assays dipsticks and the clinical high-throughput protein measurements. 
The p-value obtained indicates that this observation was statistically significant. The slope was 0.334 
with 1 being considered the ideal slope and the intercepts was 0.090 with 0 being considered the ideal 
intercept. 
Similarly, to the Siemens vs clinically laboratory results, the dataset was log transformed in order to 
normalise it to a specific range to account for the extreme differences in the measurements ranges 
between the two assays. Thus, for this Lin’s coefficient plot, Figure 3-3C shows that the majority of 
the data points lies between the 95% limits. The average agreement mean was 0.061. The rho_coef 
or concordance correlation coefficient was 0.661 with a 95% confidence interval (0.460 to 0.861), p-
value = 0.000. These results suggest poor agreement between the Life Assay dipsticks and the clinical 
high-throughput protein measurements despite log transformed. The p-value obtained indicates that 
this observation was statistically significant. The slope was 0.538 with 1 being considered the ideal 
slope and the intercepts was 1.705 with 0 being considered the ideal intercept. 
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Figure 3-3: A: Concordance correlation co-efficient of LifeAssay protein dipstick (Dprotein) vs 
clinical high-throughput protein measurements (Lprotein). B: Concordance correlation co-efficient 
of LifeAssay protein dipstick (Dprotein) vs clinical high-throughput protein measurements (Lprotein) 
Adjusted. C: Concordance correlation co-efficient of LifeAssay protein dipstick (Dprotein) vs clinical 
high-throughput protein log-transformed measurements (Lprotein).  
A - Poor concordance was observed between the LifeAssay dipstick and the clinical high-throughput measurements. 
Rho_Co-ef. = -0.08 (95% CI, -0.014 to 0.031), p-value = 0.456. B - Poor concordance was observed between the 
LifeAssay dipstick and the clinical high-throughput measurements. Rho_Co-ef. = 0.533 (95% CI, 0.475 to 0.590), p-
value = 0.000. C - Poor concordance was observed between the LifeAssay dipstick and the clinical high-throughput 
measurements. Rho_Co-ef. = 0.661 (95% CI, 0.460 to 0.861), p-value = 0.000. 
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3.1.1.4 Life Assay Creatinine Dipstick (DC) vs Laboratory High-throughput Creatinine 
(LC) 
The Lin’s coefficient graph for the LifeAssay Dipstick creatinine measurements compared with the 
clinical high-throughput creatinine measurements showed that most data points fall within the 95% 
limits (Figure 3-4A below). The average agreement mean observed was -39.849 which is not close to 
0. The rho_co-ef or concordance correlation co-efficient was 0.109 with a 95% confidence interval 
(-0.099 to 0.318), p-value = 0.304. These results suggested poor agreement between the life Assays 
dipstick’s creatinine measurements and the clinical high-throughput’s creatinine measurements. The 
p-value obtained indicated that this observation was statistically non-significant. The slope was 0.861 
with 1 being considered the ideal slope and the intercept was -20.873 with 0 being considered the 
ideal intercept. 
Similarly, to the Siemens vs clinically laboratory protein results, the creatinine data set was also log-
transformed in order to normalise it to a specific range to account for the extreme differences in the 
measurement ranges between the two assays. The Lin’s co-efficient graph for the LifeAssay 
dipstick’s creatinine, log-transformed measurements compared with the clinical high-throughput 
creatinine, log-transformed measurements shows that most data points fell within the 95% limits 
(Figure 3-4B below). The average agreement mean observed was 0.514. The rho_co-ef or 
concordance correlation co-efficient was 0.128 with a 95% confidence interval (-0.065 to 0.320), p-
value = 0.194. These results suggested poor agreement between the life Assays dipstick’s creatinine 
measurements and the clinical high-throughput’s creatinine measurements despite normalisation. The 
p-value obtained indicated that this observation was statistically non-significant. The slope was 0.709 
with 1 being considered the ideal slope and the intercept was 1.731 with 0 being considered the ideal 
intercept. 
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Figure 3-4: A: Concordance correlation co-efficient of LifeAssay creatinine dipstick (Dcreatinine) vs 
clinical high-throughput creatinine measurements (Lcreatinine). B: Concordance correlation co-
efficient of LifeAssay creatinine dipstick (Dcreatinine) vs clinical high-throughput creatinine log 
transformed measurements (Lcreatinine).  
A - Poor concordance was observed between the LifeAssay dipstick and the clinical high-throughput measurements. 
Rho_Co-ef. = 0.109 (95% CI, -0.099 to 0.318), p-value = 0.304. B - Poor concordance was observed between the 
LifeAssay dipstick and the clinical high-throughput measurements. Rho_Co-ef. = 0.128 (95% CI, -0.065 to 0.320), p-
value = 0.194. 
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In summary, all the important agreement analysis parameters have been consolidated in Table 3.1 below. 
 
 
Table 3-1: Summary of agreement analysis including the log-transformed results.  
SP = Siemens Protein Dipstick. DP = LifeAssay Protein Dipstick. LP = Laboratory High-throughput Protein. DC= LifeAssay Creatinine Dipstick. LC = Laboratory High-throughput 
Creatinine. . lnSP = log of Siemens Protein Dipstick. lnDP = log of LifeAssay Protein Dipstick. lnLP = log of Laboratory High-throughput Protein. lnDC= log of LifeAssay Creatinine 
Dipstick. lnLC = log of Laboratory High-throughput Creatinine. *significant (p < 0.001). 
 
 
SP vs DP SP vs LP 
lnSP vs 
lnLP 
DP vs LP 
DP vs LP 
(adjusted)** 
lnDP vs 
lnLP 
DC vs LC 
lnDC vs 
lnLC 
Number (#) of observations 55 55 17 68 67 16 68 68 
95% CI 0.879 to 
0.960 
-0.008-0.004 
-0.364 to -
0.516 
-0.014 to 
0.031 
0.0475 to 0.590 
0.460 to 
0.861 
-0.099 to 
0.318 
-0.065 to 
0.320 
Concordance correlation 
coefficient  
0.920 -0.002 0.076 0.008 0.533 0.661 0.109 0.128 
Average Agreement 1.818 -137.509 -0.288 -24.985 -24.985 0.061 -39.849 0.514 
P-value 0.000* 0.564 0.735 0.456 0.000* 0.000* 0.304 0.194 
Slope 0.996 -0.012 1.018 0.047 0.334 0.538 0.861 0.709 
Intercept 1.838 7.852 -0.343 6.014 0.090 1.705 -20.873 1.731 
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3.1.2  Trend analysis of each analyte over the different weeks 
Since urine was collected from the same patients over different time points throughout their 
pregnancy, it was necessary to assess how the selected analytes (Calcium, Total Protein and 
Creatinine) performed at the different time points (ADM-1, DPV8-8, DPV20-20 and DPV32-32). 
Therefore, only a sub-set, where samples were available for all time points and dipsticks and on which 
clinical lab measurements were performed, was selected for statistical trend analysis for the dipsticks 
and the high-throughput measurements. The total number of patients analysed was 56, with 14 
patients per week. 
Variance-weighted least-squares regression analysis was used to test whether the linear trend was 
significant or not and to see if there was an increase over the weeks for each dipstick and laboratory 
result, respectively. Goodness-of-fit chi2 was used to test whether the single population fitted the 
hypothesised distribution. Then the model fit chi2 was used to compare the weeks to each other (across 
categories). All the important parameters observed have been summarised in Table 3-2 . In order to 
display the trends for the respective analytes per respective assay visually, the mean value and the 
corresponding 95% confidence interval was plotted in subsequent graphs (Figure 3-5 to 3-7). The 
dipstick assays and laboratory-based assays were also compared to determine whether the same trend 
was observed in both types of assays. 
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Table 3-2: Summary of Variance-weighted least-squares regression and chi2 test over the weeks  
DProtein = LifeAssay Protein Dipstick. LProtein = Laboratory High-throughput Protein. DCreatinine= LifeAssay 
Creatinine Dipstick. LCreatinine = Laboratory High-throughput Creatinine. LCalcium = Laboratory High-throughput 
Calcium. *significant (p < 0.001). 
 LProtein DProtein LCreatinine DCreatinine LCalcium 
# of observations 56 56 56 56 56 
Mean 17.7 19 133.6 14.8 7.3 
95% CI 12-23 12-25 119-147 1-27 4-10 
Coefficient  0.3545141 0.2275635 1.12994 4.215532 0.3132418 
P-value 0.236 0.407 0.114 0.000* 0.022 
Goodness-of-fit chi2 3.35 1.91 5.18 8.64 1.53 
Model chi2 1.41 0.69 2.50 46.64 5.28 
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3.1.2.1 Laboratory High-throughput Creatinine (LC) vs Life Assay Creatinine 
measurements (DC) 
The variance-weighted least-squares regression graph (Figure 3-5A) demonstrating clinical high-
throughput creatinine measurements over the weeks showed a higher mean value for week 8 (DPV8) 
compared with the other weeks. In comparison, the variance-weighted least-squares regression graph 
(Figure 3-5B) displaying the dipstick-based creatinine measurements showed the highest value for 
week 20 (DPV20), followed by week 32 (DPV32).  
 
A 
 
B* 
Figure 3-5: A: Variance-weighted least-squares regression of Laboratory High-throughput 
Creatinine (LC) and B: LifeAssay Creatinine Dipstick (DC).  
Total number of patients was 56, with 14 patients each week, A – co-efficient. = 1.12994 (increase per week), P value = 
0.114; not significant, B – co-efficient. = 4.215532 (increase per week), P-value = 0.000. *Significant p<0.001. 
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3.1.2.2 Laboratory High-throughput Protein (LP) vs Siemens and LifeAssay Dipstick 
Protein measurements (DP) 
For the protein trend analysis for the two assays, variance-weighted least-squares regression graph 
(Figure 3-6A) specifically for the laboratory protein measurements showed a higher value for week 
32 (DPV32). The variance-weighted least-squares regression graph for the LifeAssay dipstick protein 
measurements (Figure 3-6B) also showed a higher value for week 32, similar to the laboratory-based 
protein trend analysis.  
 
A 
 
B 
Figure 3-6: A: Variance-weighted least-squares regression of Laboratory High-throughput Protein 
(LP) and B: Life Assay Protein Dipstick (DP).  
Total number of patients was 56, with 14 patients each week, A – co-efficient. = 0.3545141 (increase per week), P-value 
= 0.236, not significant; B. – co-efficient. = 0.2275635 (increase per week), P-value = 0.407, not significant. 
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3.1.2.3 Laboratory High-throughput Calcium (LCa) trend analysis 
Calcium measurements were performed using only the laboratory-based assays. The Variance-
weighted least-squares regression graph (Figure 3-7) showed an increasing trend, following the 
baseline week until a plateau was reached. 
 
Figure 3-7: Variance-weighted least-squares regression of Laboratory High-throughput Calcium 
(LCa).  
Total number of patients was 56, with 14 patients each week; co-efficient. = 0.3132418 (increase per week), P-value = 
0.022, not significant. 
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3.2 Objective 2: Adipsin 
For the ELISA-based results, the analysis was computed using Excel 2016 to create the standard 
curve for both the original and adjusted results, to acquire the R2 value and equation to calculate the 
%CV value to measure intra- and inter-assay. The adjusted results came from the standard curve. 
When the original standard curve was calculated to get the R2 value, it was observed to be low for 
both plates. Thus, after removing the 40ng/ul concentration and its associated OD value, the R2 value 
improved. Therefore, both the original and the adjusted outcomes have been included. 
3.2.1 Standard Curve 
3.2.1.1 Standard Curve 
The original standard curve including the 40ng/ul concentration and OD value is shown in Figure 3-
8. Plate 1 generated an equation of y = 104.38x + 663.07 and a R2 value of 0.8897. Plate 2 generated 
an equation of y = 86.92x + 639.47 and a R2 value of 0.929. The original results for the calculated 
concentrations of each sample are in Section 3.2.3.  
 
Figure 3-8: Standard curve calculated for each plate with their respective equations and R2 values.  
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3.2.1.2 Adjusted Standard Curve 
The adjusted standard curve excluding the 40ng/ul concentration and OD value is shown in Figure 3-
9. Plate 1 generated an equation of y = 169.16x + 382.61 and a R2 value of 0.9872. Plate 2 generated 
an equation of y = 127.09x + 465.55 and a R2 value of 0.9763. The adjusted results for the calculated 
concentrations of each sample are in Section 3.2.3. 
 
Figure 3-9: Standard curve calculated for each plate and adjusted, with their respective equations 
and R2 values.  
The 40ng/ul concentration and associated OD value were removed for both plates. 
3.2.2 Intra-Assay of OD Values 
When the ELISA-based process is used, two measures of the Co-efficient of Variability (CV) are 
reported. The Inter-Assay CV (plate-to-plate consistency) and the Intra-Assay CV (an average value 
calculated from the individual CVs) in order to express the precision or repeatability of the process. 
CV is a dimensionless number defined as the standard deviation of a set of measurements divided by 
the mean of the set. The %CV was calculated for the OD values and the concentrations (Section 
3.2.3). The concentrations %CV has not been emphasised as they were negative values and are 
discussed in Chapter 4.  
Table 3-3 and Table 3-4 below show the results from the two plates, starting with the sample, each 
of which had a week attached (4 per sample), the plate on which it was processed, then the triplicate 
OD Value Results, then the Mean, Standard Deviation and finally the %CV which is Mean divided 
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by Standard Deviation. Plate 1 had a range of %CV values from 0.841% to 22.701%. Plate 2 had a 
range of %CV values from 1.797% to 48.951%. 
Inter-assay %CVs of <15% are generally acceptable. Intra-assay %CVs should be <10%. These 
scores reflect the performance of the user who handled the assay. The %CVs that are >10% reflect 
poor pipetting technique of the user. It is the norm to use %CVs of the concentrations, but here the 
OD values %CVs have been emphasised. 
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Table 3-3: Intra-assay table of the OD Values for Plate 1.  
Each sample had a week, then on which plate it was processed, then the triplicate OD Value Results, then the 
Mean, Standard Deviation and finally the %CV which is Mean divided by Standard Deviation. 
 
 
  
Sample Week Plate Result 1 Result 2 Result 3 Mean Standard Dev %CV
4438-787 1 1 504 584 632 573.33 52.797 9.209
4438-787 8 1 297 299 353 316.33 25.940 8.200
4438-787 20 1 142 148 119 136.33 12.499 9.168
4438-787 32 1 187 181 162 176.67 10.656 6.032
4455-796 1 1 428 419 403 416.67 10.339 2.481
4455-796 8 1 206 204 226 212.00 9.933 4.685
4455-796 20 1 310 306 319 311.67 5.437 1.744
4455-796 32 1 592 606 591 596.33 6.848 1.148
4456-797 1 1 139 122 168 143.00 18.991 13.281
4456-797 8 1 149 175 182 168.67 14.197 8.417
4456-797 20 1 167 185 176 176.00 7.348 4.175
4456-797 32 1 276 211 237 241.33 26.712 11.069
4462-807 1 1 200 179 175 184.67 10.965 5.938
4462-807 8 1 207 158 173 179.33 20.499 11.431
4462-807 20 1 179 174 193 182.00 8.042 4.418
4462-807 32 1 236 258 257 250.33 10.143 4.052
4466-814 1 1 181 171 189 180.33 7.364 4.083
4466-814 8 1 312 311 318 313.67 3.091 0.986
4466-814 20 1 211 216 125 184.00 41.769 22.701
4466-814 32 1 201 164 183 182.67 15.107 8.270
4470-817 1 1 323 322 296 313.67 12.499 3.985
4470-817 8 1 298 305 348 317.00 22.106 6.973
4470-817 20 1 210 220 220 216.67 4.714 2.176
4470-817 32 1 1821 1677 1754 1750.67 58.835 3.361
4471-818 1 1 963 965 947 958.33 8.055 0.841
4471-818 8 1 212 231 206 216.33 10.656 4.926
4471-818 20 1 171 190 152 171.00 15.513 9.072
4471-818 32 1 160 185 144 163.00 16.872 10.351
4473-820 1 1 192 172 209 191.00 15.122 7.917
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Table 3-4: Intra-assay table of the OD Values for Plate 2.  
Each sample had a week, then on which plate it was processed, then the triplicate OD Value Results, then the 
Mean, Standard Deviation and finally the %CV which is Mean divided by Standard Deviation. Highlighted 
grey area of value 473 is the known pipetting error, whereby too much substrate was added to the well.  
 
  
Sample Week Plate Result 1 Result 2 Result 3 Mean Standard Dev %CV
4473-820 8 2 210 201 203 204.67 3.859 1.885
4473-820 20 2 254 275 244 257.67 12.919 5.014
4473-820 32 2 286 298 286 290.00 5.657 1.951
4480-838 1 2 272 254 238 254.67 13.888 5.454
4480-838 8 2 254 242 257 251.00 6.481 2.582
4480-838 20 2 343 270 296 303.00 30.210 9.970
4480-838 32 2 257 274 283 271.33 10.781 3.973
4614-1033 1 2 274 245 271 263.33 13.021 4.945
4614-1033 8 2 143 152 142 145.67 4.497 3.087
4614-1033 20 2 181 177 217 191.67 17.988 9.385
4614-1033 32 2 364 369 300 344.33 31.415 9.123
4624-1045 1 2 200 199 217 205.33 8.260 4.023
4624-1045 8 2 207 237 200 214.67 16.049 7.476
4624-1045 20 2 376 286 327 329.67 36.791 11.160
4624-1045 32 2 261 254 274 263.00 8.287 3.151
4765-1199 1 2 226 228 242 232.00 7.118 3.068
4765-1199 8 2 195 186 211 197.33 10.339 5.239
4765-1199 20 2 150 214 262 208.67 45.879 21.987
4765-1199 32 2 209 459 151 273.00 133.636 48.951
4777-1209 1 2 213 236 209 219.33 11.898 5.424
4777-1209 8 2 473 236 268 325.67 104.996 32.240
4777-1209 20 2 236 187 189 204.00 22.642 11.099
4777-1209 32 2 196 231 255 227.33 24.226 10.657
4485-843 1 2 311 261 231 267.67 32.998 12.328
4485-843 8 2 201 193 200 198.00 3.559 1.797
4485-843 20 2 198 180 188 188.67 7.364 3.903
4485-843 32 2 230 227 186 214.33 20.072 9.365
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Table 3-5 below shows the average intra-assay %CV for the two plates. Plate 1 had an average mean 
of 325, average standard deviation of 17 and an average %CV of 6.6%. Plate 2 had an average mean 
of 242, average standard deviation of 24 and an average %CV of 9.2%. Despite Plate 1 having a better 
%CV result, they were both below <10%. The average %CV across the plates is 7.9% which is also 
<10%. 
Table 3-5: Average Mean, Standard Deviation and %CV for the OD Values. 
 
Average Mean 
Average Standard 
Deviation 
Average %CV 
Average %CV 
across plates 
Plate 1 325 17 6.6 
7.9 
Plate 2 242 24 9.2 
3.2.3 Concentration (ng/ul) results from OD Values 
Table 3-6 and Table 3-7 below show the results using the original equation to calculate the 
concentrations from the OD values. The mean, standard deviation and %CV were also calculated 
from the concentrations. It was noted that most of the concentration results were negative and thus 
produced %CV values that were negative and could not be used.  
Table 3-8 and Table 3-9 below show the t results using the adjusted equation to calculate the 
concentrations from the OD values. The mean, standard deviation and %CV were also calculated 
from the concentrations. It was noted that, despite the adjustment, most of the concentration results 
were negative and produced negative %CV values. 
Plate 2 had a highlighted grey value of 473 which was a pipetting error. Too much substrate was 
added to the well by accident. The negative concentrations and %CV values have been discussed 
further in Chapter 4. 
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Table 3-6: Plate 1 Concentration values calculated from the OD Values using the original equation 
calculated.  
Each sample had a week, then on which plate it was processed, then the triplicate OD Value Results, then the 
calculated concentration, then the Mean, Standard Deviation and finally the %CV which is Mean divided by 
Standard Deviation. The Mean, Standard Deviation and %CV were calculated from the concentration results. 
 
  
Sample Week Plate Result 1 Result 2 Result 3 [Result 1] [Result 2] [Result 3] [Mean] Standard Dev %CV
4438-787 1 1 504 584 632 -2.68 -1.88 -1.40 -1.99 0.526 -26.468
4438-787 8 1 297 299 353 -4.74 -4.72 -4.19 -4.55 0.259 -5.683
4438-787 20 1 142 148 119 -6.29 -6.23 -6.52 -6.35 0.125 -1.964
4438-787 32 1 187 181 162 -5.84 -5.90 -6.09 -5.94 0.106 -1.788
4455-796 1 1 428 419 403 -3.44 -3.53 -3.69 -3.55 0.103 -2.903
4455-796 8 1 206 204 226 -5.65 -5.67 -5.45 -5.59 0.099 -1.771
4455-796 20 1 310 306 319 -4.61 -4.65 -4.52 -4.60 0.054 -1.179
4455-796 32 1 592 606 591 -1.80 -1.66 -1.81 -1.76 0.068 -3.880
4456-797 1 1 139 122 168 -6.32 -6.49 -6.03 -6.28 0.189 -3.015
4456-797 8 1 149 175 182 -6.22 -5.96 -5.89 -6.02 0.142 -2.350
4456-797 20 1 167 185 176 -6.04 -5.86 -5.95 -5.95 0.073 -1.231
4456-797 32 1 276 211 237 -4.95 -5.60 -5.34 -5.30 0.266 -5.026
4462-807 1 1 200 179 175 -5.71 -5.92 -5.96 -5.86 0.109 -1.864
4462-807 8 1 207 158 173 -5.64 -6.13 -5.98 -5.92 0.204 -3.454
4462-807 20 1 179 174 193 -5.92 -5.97 -5.78 -5.89 0.080 -1.361
4462-807 32 1 236 258 257 -5.35 -5.13 -5.14 -5.21 0.101 -1.941
4466-814 1 1 181 171 189 -5.90 -6.00 -5.82 -5.91 0.073 -1.243
4466-814 8 1 312 311 318 -4.59 -4.60 -4.53 -4.58 0.031 -0.673
4466-814 20 1 211 216 125 -5.60 -5.55 -6.46 -5.87 0.416 -7.094
4466-814 32 1 201 164 183 -5.70 -6.07 -5.88 -5.88 0.151 -2.560
4470-817 1 1 323 322 296 -4.48 -4.49 -4.75 -4.58 0.125 -2.722
4470-817 8 1 298 305 348 -4.73 -4.66 -4.24 -4.54 0.220 -4.850
4470-817 20 1 210 220 220 -5.61 -5.51 -5.51 -5.54 0.047 -0.848
4470-817 32 1 1821 1677 1754 10.45 9.01 9.78 9.75 0.587 6.017
4471-818 1 1 963 965 947 1.90 1.92 1.74 1.85 0.080 4.342
4471-818 8 1 212 231 206 -5.59 -5.40 -5.65 -5.55 0.106 -1.915
4471-818 20 1 171 190 152 -6.00 -5.81 -6.19 -6.00 0.155 -2.578
4471-818 32 1 160 185 144 -6.11 -5.86 -6.27 -6.08 0.168 -2.767
4473-820 1 1 192 172 209 -5.79 -5.99 -5.62 -5.80 0.151 -2.599
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Table 3-7: Plate 2 Concentration values calculated from the OD Values using the original equation 
calculated.  
Each sample had a week, then on which plate it was processed, then the triplicate OD Value Results, then the 
calculated concentration, then the Mean, Standard Deviation and finally the %CV which is Mean divided by 
Standard Deviation. The Mean, Standard Deviation and %CV were calculated from the concentration results. 
Highlighted grey area of value 473 is the known pipetting error, whereby too much substrate was added to the 
well. 
 
  
Sample Week Plate Result 1 Result 2 Result 3 [Result 1] [Result 2] [Result 3] [Mean] Standard Dev %CV
4473-820 8 2 210 201 203 -6.16 -6.27 -6.25 -6.23 0.046 -0.740
4473-820 20 2 254 275 244 -5.64 -5.39 -5.76 -5.59 0.154 -2.759
4473-820 32 2 286 298 286 -5.25 -5.11 -5.25 -5.21 0.068 -1.298
4480-838 1 2 272 254 238 -5.42 -5.64 -5.83 -5.63 0.166 -2.948
4480-838 8 2 254 242 257 -5.64 -5.78 -5.60 -5.67 0.077 -1.365
4480-838 20 2 343 270 296 -4.57 -5.45 -5.13 -5.05 0.361 -7.145
4480-838 32 2 257 274 283 -5.60 -5.40 -5.29 -5.43 0.129 -2.372
4614-1033 1 2 274 245 271 -5.40 -5.74 -5.43 -5.53 0.156 -2.815
4614-1033 8 2 143 152 142 -6.96 -6.86 -6.97 -6.93 0.054 -0.775
4614-1033 20 2 181 177 217 -6.51 -6.56 -6.08 -6.38 0.215 -3.367
4614-1033 32 2 364 369 300 -4.32 -4.26 -5.09 -4.56 0.375 -8.235
4624-1045 1 2 200 199 217 -6.28 -6.29 -6.08 -6.22 0.099 -1.587
4624-1045 8 2 207 237 200 -6.20 -5.84 -6.28 -6.11 0.192 -3.140
4624-1045 20 2 376 286 327 -4.18 -5.25 -4.76 -4.73 0.440 -9.287
4624-1045 32 2 261 254 274 -5.55 -5.64 -5.40 -5.53 0.099 -1.790
4765-1199 1 2 226 228 242 -5.97 -5.95 -5.78 -5.90 0.085 -1.441
4765-1199 8 2 195 186 211 -6.34 -6.45 -6.15 -6.31 0.124 -1.956
4765-1199 20 2 150 214 262 -6.88 -6.11 -5.54 -6.18 0.548 -8.871
4765-1199 32 2 209 459 151 -6.17 -3.19 -6.87 -5.41 1.596 -29.511
4777-1209 1 2 213 236 209 -6.13 -5.85 -6.17 -6.05 0.142 -2.349
4777-1209 8 2 473 236 268 -3.02 -5.85 -5.47 -4.78 1.254 -26.238
4777-1209 20 2 236 187 189 -5.85 -6.44 -6.41 -6.23 0.270 -4.339
4777-1209 32 2 196 231 255 -6.33 -5.91 -5.62 -5.96 0.289 -4.860
4485-843 1 2 311 261 231 -4.96 -5.55 -5.91 -5.47 0.394 -7.202
4485-843 8 2 201 193 200 -6.27 -6.37 -6.28 -6.31 0.043 -0.674
4485-843 20 2 198 180 188 -6.31 -6.52 -6.43 -6.42 0.088 -1.371
4485-843 32 2 230 227 186 -5.92 -5.96 -6.45 -6.11 0.240 -3.924
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Table 3-8: Plate 1 Concentration values calculated from the OD Values using the adjusted equation 
calculated.  
Each sample had a week, then on which plate it was processed, then the triplicate OD Value Results, then the 
calculated concentration, then the Mean, Standard Deviation and finally the %CV which is Mean divided by 
Standard Deviation. The Mean, Standard Deviation and %CV were calculated from the concentration results. 
 
  
Sample Week Plate Result 1 Result 2 Result 3 [Result 1] [Result 2] [Result 3] [Mean] Standard Dev %CV
4438-787 1 1 504 584 632 0.72 1.19 1.47 1.13 0.312 27.683
4438-787 8 1 297 299 353 -0.51 -0.49 -0.18 -0.39 0.153 -39.139
4438-787 20 1 142 148 119 -1.42 -1.39 -1.56 -1.46 0.074 -5.075
4438-787 32 1 187 181 162 -1.16 -1.19 -1.30 -1.22 0.063 -5.174
4455-796 1 1 428 419 403 0.27 0.22 0.12 0.20 0.061 30.357
4455-796 8 1 206 204 226 -1.04 -1.06 -0.93 -1.01 0.059 -5.822
4455-796 20 1 310 306 319 -0.43 -0.45 -0.38 -0.42 0.032 -7.663
4455-796 32 1 592 606 591 1.24 1.32 1.23 1.26 0.040 3.204
4456-797 1 1 139 122 168 -1.44 -1.54 -1.27 -1.42 0.112 -7.926
4456-797 8 1 149 175 182 -1.38 -1.23 -1.19 -1.26 0.084 -6.636
4456-797 20 1 167 185 176 -1.27 -1.17 -1.22 -1.22 0.043 -3.557
4456-797 32 1 276 211 237 -0.63 -1.01 -0.86 -0.84 0.158 -18.908
4462-807 1 1 200 179 175 -1.08 -1.20 -1.23 -1.17 0.065 -5.539
4462-807 8 1 207 158 173 -1.04 -1.33 -1.24 -1.20 0.121 -10.084
4462-807 20 1 179 174 193 -1.20 -1.23 -1.12 -1.19 0.048 -4.009
4462-807 32 1 236 258 257 -0.87 -0.74 -0.74 -0.78 0.060 -7.668
4466-814 1 1 181 171 189 -1.19 -1.25 -1.14 -1.20 0.044 -3.640
4466-814 8 1 312 311 318 -0.42 -0.42 -0.38 -0.41 0.018 -4.484
4466-814 20 1 211 216 125 -1.01 -0.98 -1.52 -1.17 0.247 -21.031
4466-814 32 1 201 164 183 -1.07 -1.29 -1.18 -1.18 0.089 -7.556
4470-817 1 1 323 322 296 -0.35 -0.36 -0.51 -0.41 0.074 -18.129
4470-817 8 1 298 305 348 -0.50 -0.46 -0.20 -0.39 0.131 -33.693
4470-817 20 1 210 220 220 -1.02 -0.96 -0.96 -0.98 0.028 -2.841
4470-817 32 1 1821 1677 1754 8.50 7.65 8.11 8.09 0.348 4.301
4471-818 1 1 963 965 947 3.43 3.44 3.34 3.40 0.048 1.399
4471-818 8 1 212 231 206 -1.01 -0.90 -1.04 -0.98 0.063 -6.409
4471-818 20 1 171 190 152 -1.25 -1.14 -1.36 -1.25 0.092 -7.331
4471-818 32 1 160 185 144 -1.32 -1.17 -1.41 -1.30 0.100 -7.683
4473-820 1 1 192 172 209 -1.13 -1.25 -1.03 -1.13 0.089 -7.892
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Table 3-9: Plate 2 Concentration values calculated from the OD Values using the adjusted equation 
calculated.  
Each sample had a week, then on which plate it was processed, then the triplicate OD Value Results, then the 
calculated concentration, then the Mean, Standard Deviation and finally the %CV which is Mean divided by 
Standard Deviation. The Mean, Standard Deviation and %CV were calculated from the concentration results. 
Highlighted grey area of value 473 is the known pipetting error, whereby too much substrate was added to the 
well. 
 
3.3 Objective 3: Storage 
The majority of the sample cohort comprised archived samples with no baseline measurements and a 
lack of pre-variables data that could potentially influence analyte integrity. Therefore, it was decided 
to determine how an analysis of fresh urine samples, processed according to the gold standard method 
would compare with various scenarios that might have taken place in the clinic when urine samples 
was obtained in real life. 
Thus, for this analysis, the Wilcoxon Signed-Rank Test was used and the analytes for each group 
(Group 2, 3 & 4) was compared with the reference group (Group 1) using an average of the 19 
patients. The Wilcoxon Signed-Rank Test assesses how different the groups are from the reference 
Sample Week Plate Result 1 Result 2 Result 3 [Result 1] [Result 2] [Result 3] [Mean] Standard Dev %CV
4473-820 8 2 210 201 203 -2.01 -2.08 -2.07 -2.05 0.030 -1.479
4473-820 20 2 254 275 244 -1.66 -1.50 -1.74 -1.64 0.102 -6.214
4473-820 32 2 286 298 286 -1.41 -1.32 -1.41 -1.38 0.045 -3.222
4480-838 1 2 272 254 238 -1.52 -1.66 -1.79 -1.66 0.109 -6.586
4480-838 8 2 254 242 257 -1.66 -1.76 -1.64 -1.69 0.051 -3.021
4480-838 20 2 343 270 296 -0.96 -1.54 -1.33 -1.28 0.238 -18.585
4480-838 32 2 257 274 283 -1.64 -1.51 -1.44 -1.53 0.085 -5.551
4614-1033 1 2 274 245 271 -1.51 -1.74 -1.53 -1.59 0.102 -6.439
4614-1033 8 2 143 152 142 -2.54 -2.47 -2.55 -2.52 0.035 -1.406
4614-1033 20 2 181 177 217 -2.24 -2.27 -1.96 -2.16 0.142 -6.568
4614-1033 32 2 364 369 300 -0.80 -0.76 -1.30 -0.95 0.247 -25.916
4624-1045 1 2 200 199 217 -2.09 -2.10 -1.96 -2.05 0.065 -3.174
4624-1045 8 2 207 237 200 -2.03 -1.80 -2.09 -1.97 0.126 -6.397
4624-1045 20 2 376 286 327 -0.70 -1.41 -1.09 -1.07 0.289 -27.075
4624-1045 32 2 261 254 274 -1.61 -1.66 -1.51 -1.59 0.065 -4.091
4765-1199 1 2 226 228 242 -1.88 -1.87 -1.76 -1.84 0.056 -3.048
4765-1199 8 2 195 186 211 -2.13 -2.20 -2.00 -2.11 0.081 -3.855
4765-1199 20 2 150 214 262 -2.48 -1.98 -1.60 -2.02 0.361 -17.860
4765-1199 32 2 209 459 151 -2.02 -0.05 -2.48 -1.52 1.052 -69.403
4777-1209 1 2 213 236 209 -1.99 -1.81 -2.02 -1.94 0.094 -4.832
4777-1209 8 2 473 236 268 0.06 -1.81 -1.55 -1.10 0.826 -75.060
4777-1209 20 2 236 187 189 -1.81 -2.19 -2.18 -2.06 0.178 -8.657
4777-1209 32 2 196 231 255 -2.12 -1.85 -1.66 -1.87 0.191 -10.170
4485-843 1 2 311 261 231 -1.22 -1.61 -1.85 -1.56 0.260 -16.676
4485-843 8 2 201 193 200 -2.08 -2.14 -2.09 -2.11 0.028 -1.330
4485-843 20 2 198 180 188 -2.11 -2.25 -2.18 -2.18 0.058 -2.659
4485-843 32 2 230 227 186 -1.85 -1.88 -2.20 -1.98 0.158 -7.990
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group. The Wilcoxon Sign-Rank Test was used as the data set was skewed. The data were a matched 
data set (measurements were from the same individuals but under different conditions). 
Table 3-10, below summarises the Median, Mean and Standard Deviation for each analyte in each 
group. For some of the analytes, it was noticed that the Median and Mean were not similar, whereas 
others were very similar. Based on the Median versus Mean values for Urea, a large difference was 
observed between the Median = 366.4667 and Mean = 319.9263 in Group 1.  
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Table 3-10: Summary of results for each group, looking at the Median, Mean and Standard Deviation 
using the Wilcoxon Signed-Rank Test.  
** Indicates the Medians that were significantly different from each other for each analyte. 
 
Urea Creatinine Calcium Protein Albumin 
G
ro
u
p
 1
 
(R
ef
er
en
c
e)
 
Median 366.4667 10.93333** 2.733333** 0.06** 3.466667 
Mean 319.9263 11.26491 3.37807 0.0677193 9.554386 
Standard 
Deviation 
166.917 6.030811 2.837593 0.0437734 18.20232 
G
ro
u
p
 2
  
(4
 o
C
) 
Median 366.7333 10.93333 2.726667 0.06 3.633333 
Mean 321.1667 11.19474 3.364561 0.0638596 9.65614 
Standard 
Deviation 
166.7052 5.944094 2.814591 0.0452328 18.03708 
G
ro
u
p
 3
 
(2
8
 o
C
) 
Median 368.2333 10.73333** 2.18** 0.0733333** 3.4 
Mean 320.4202 11.14386 3.198596 0.0814035 9.563158 
Standard 
Deviation 
166.8813 5.973026 2.872127 0.0497688 17.91448 
G
ro
u
p
 4
 
(n
o
 c
en
tr
if
u
g
a
ti
o
n
) Median 364.4333 10.9 2.853333 0.06 3.533333 
Mean 320.2193 11.22632 3.672807 0.0663158 9.580702 
Standard 
Deviation 
166.1031 6.011795 3.007545 0.0424394 17.90039 
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Table 3-11 below indicates the different p-values for each group comparison to the reference. It was 
noted that for Creatinine, Calcium and Protein, in the comparison of Group 3 to the reference, it was 
highly significant (p<0.05) and therefore different to the reference.  
Table 3-11: P-values for each group in comparison with the reference for each analyte.  
*Significant (p<0.05). 
 Urea Creatinine Calcium Protein Albumin 
Group 1 vs Group 2 0.8721 0.0947 0.6148 0.1050 0.1473 
Group 1 vs Group 3 0.9679 0.0022* 0.0079* 0.0165* 0.4565 
Group 1 vs Group 4 0.9359 0.1837 0.1416 0.5435 0.3236 
 
Figure 3-8 below represents Table 3-11 as a bar chart depicting each of the p values; those closest to 
0 (*Significant is p<0.05) were the creatinine, calcium and protein from the Group 3 versus Group 1 
(reference). 
 
Figure 3-10: Table 3-11 depicted as a bar chart.  
Group 1 vs 3 for creatinine, calcium and protein were significant. *Significant (p<0.05). 
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Chapter 4  
Discussion 
The effect of storage time and temperature on bio-marker levels in urine is not well understood as it 
is methodologically challenging to obtain measurements over various time points over extended time 
periods to study. Thus, in this exploratory study, the research question was to evaluate the long-term 
stability of select analytes in preservative-free urine in a pre-eclampsia cohort. Since this study 
formed part of a larger study titled: Advancing a protein to creatinine rapid test for determining 
proteinuria status as an onset indicator of pre-eclampsia, the present investigation would help to 
establish priorities for the larger study in terms of selected analytes to be measured, improve final 
research design and determine best data collection and analysis methods. Therefore, in order to 
provide context, the focus was on the bio-banking aspects, which included pre-analytical variables as 
well as sample processing and handling, and storage conditions, all of which could contribute to the 
effect on sample integrity. Therefore, for the present investigation, Calcium, Creatinine and Total 
Protein in long-term, stored, urine samples were measured using both manual dipstick as well as high-
throughput laboratory measurements and these assays were compared using agreement analysis. 
Additionally, the diagnostic and prognostic potential of an ELISA-based Adipsin or Complement 
Factor D (CFD) test for pre-eclampsia was evaluated on long-term, stored, urine samples. 
Furthermore, because of the lack of baseline measurements for the larger study, fresh urine samples 
were collected to evaluate different processing and intermediate storage conditions compared with 
the gold standard to determine to what extent pre-analytical variables could affect sample integrity 
on selected analytes.  
4.1 Comparison of clinically high-throughput measurements versus the 
newly developed LifeAssay Dipstick and the gold standard Siemens 
Dipstick 
For objective 1, agreement analysis was performed on the laboratory high-throughput measurements 
and the dipsticks for creatinine and total protein, as both analytes are important bio-markers for pre-
eclampsia in long-term, stored urine. In addition, calcium levels were obtained from high-throughput 
measurements with the underlying question of whether it would be measurable despite the long-term 
storage of the urine samples. Secondly, as the urine samples was obtained from the same people 
throughout their pregnancy over different time points, a trend analysis over the weeks was performed 
in order to determine whether there was a pattern of increase or decrease in selected analytes.  
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4.1.1 Agreement between laboratory high-throughput versus dipsticks 
In the comparison to test the agreement between the laboratory high-throughput and the dipsticks, the 
concordance correlation co-efficient (Lin’s co-efficient or CCC) was used (Lin, 1989; 2000), which 
has a scale ranging between -1 (perfect negative agreement) and 1 (perfect agreement)). The 
concordance correlation co-efficient combines measures of both precision and accuracy to determine 
how far the observed data deviate from the line of perfect concordance (y=0). Lin's co-efficient 
increases in value as a function of the nearness of the data's reduced major axis to the line of perfect 
concordance (the accuracy of the data) and of the tightness of the data about its reduced major axis 
(the precision of the data). Therefore, the closer the value of rho_co-ef is to 1, the more correlated the 
data is between the two data sets. CCC is a more appropriate statistic than the Pearson correlation co-
efficient for assessing the level of agreement between two measurements of the same item. This is 
because the latter only quantifies the linear relationship whereas the former quantifies the linear 
relationship under the assumption that the slope equals 1 and the intercept equals 0. In addition to 
calculating estimates of the CCC, the 95% confidence intervals (CIs) were also calculated. The CCC 
was required to exceed 0.90 and 0.80 in order to claim that the paired measurements of a urinary bio-
marker had excellent and good agreement, respectively, under the two conditions of each process. 
It was assumed that the data set results would be the same for all the weeks and Week 32 was selected 
specifically for the agreement analysis (Lin’s Co-efficient). In addition, for calcium measurement 
analysis, the last week was optimal to use because of the additional calcium supplements given to 
pregnant women in the last weeks of their pregnancy. For the protein measurements, the two dipsticks 
(Siemens - SP vs LifeAssay - DP) were compared with each other before the respective dipsticks 
were compared with the clinical laboratory measurements in the agreement analysis. In the age of 
point of care, dipsticks are used as a cheaper alternative to the high-throughput measurements in the 
case of developing countries. 
In addition, it was noted that creatinine was only measureable on the LifeAssay Dipstick and not the 
Siemens Dipstick; therefore, the LifeAssay results were compared with the clinical laboratory 
measurement for agreement. 
The Siemens Dipstick protein measurements (SP) were compared with the LifeAssay Dipstick protein 
measurements (DP). It was observed that the data correlated between the two dipsticks for the protein 
result. The rho_ co-efficient or concordance correlation coefficient was 0.920 which is close to one 
with a statistically significant p-value suggesting substantial agreement between the two dipsticks. 
As the results for protein analysis were congruent and similar, this indicated that the newly developed 
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LifeAssay Dipstick is on par with the diagnostic certified Siemens dipstick (Gold Standard) that is 
used in the laboratories globally. In order to implement the LifeAssay Dipstick as a more cost-
effective assay than the Siemens in low- and middle-income countries (LIMC), this concordant result 
is of value to the larger study and is in line with what was expected. In turn, this study was also able 
to demonstrate that, despite the long-term storage of these urine samples, the specific analytes were 
still measurable in this specific cohort.   
The gold standard, Siemens Dipstick protein results (SP) were compared with the laboratory protein 
result (LP), which was not significant, which meant the results were not similar and in agreement. 
The finding may be attributed most likely to the fact that a dipstick measurement will not always be 
exactly the same as a laboratory result. The high-throughput result uses specific equipment to 
determine the exact value (objective quantitative measurement), demonstrating that it is more 
sensitive whereas the dipstick is used for a more generalised view of what the possible value could 
be. The dipstick is also a subjective measurement relying on the user’s perception of colour intensities 
which could also skew the results because of the big differences in measurement ranges. The data 
were log-transformed in order to normalise them to a specific range to account for the extreme 
differences in the measurements ranges between the two assays. However, despite the transformation, 
the agreement between the assay and the laboratory results was still poor. 
Similarly, the LifeAssay Dipstick protein results (DP) were compared with the laboratory protein 
results (LP). In these protein measurements, an extreme outlier was observed which affected the 
initial calculations resulting in poor agreement and non-significance. It is very likely that the patient 
had an abnormally high value. The analysis was re-run excluding the outlier. In this case, the 
concordance correlation co-efficient improved from an extreme negative value to the value of 0.533 
with a significant p-value demonstrating how the outlier skewed the results significantly. However, 
despite the significance, the agreement between the assay and the laboratory results was still poor. 
The data was log-transformed in order to normalise it to a specific range to account for the extreme 
differences in the measurement ranges between the two assays. However, despite the transformation, 
the agreement between the assay and the laboratory results was still poor with a concordance 
correlation co-efficient of 0.661 and a significant p-value of 0.000.observed. 
For the subsequent creatinine results, the LifeAssay Dipstick results were compared with the 
laboratory creatinine results. Similar to the protein result, poor agreement and no significance was 
observed. Although the creatinine dipstick was newly developed, it was expected that there would, at 
least, be agreement between the values, even if it was not significant. In this case, it could be that the 
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sample size was too small or the values were over-estimated or under-estimated in the dipstick results. 
It is very easy to over or under-estimate subjective values and this could be the cause, but it was more 
likely a combination of subjective interpretation and a small sample size.  
It is noted that, despite the non-significant values, this thesis was an exploratory pilot carried out on 
the existing data to determine whether there was an observable trend or pattern. Only one week was 
used for analysis which ranged between 55-68 observations that were included, thus the sample size 
was very small. This could have attributed to the non-significant values observed. However, the main 
factors contributing to non-significance can be attributed most likely to the subjective values of the 
dipsticks and, more importantly, the big difference in measurement ranges between the dipsticks and 
the laboratory results. This observation was confirmed by the significant values and the concordant 
agreement observed between the two dipsticks for the protein results, which was very informative. 
This agreement could also be attributable to the same measurement ranges for the two dipsticks 
compared with the laboratory measurements. This result was expected to be significant as the new 
dipstick was developed in line with known and certified values of the Siemens dipstick, which is the 
gold standard used. 
With regards to the effect of long-term storage on sample integrity, owing to the lack of baseline 
measurements for this cohort, it would be difficult to infer differences related to storage time from 
differences related to biological or assay variability. Therefore, this matter for this objective has not 
been pursued further, which is a limitation of this study.  
4.1.2 Trend analysis of measurements over various time points  
For the trend analysis, at each time point (ADM-1, DPV8-8, DPV20-20 and DPV32-32), the mean 
value and the corresponding 95% confidence interval were plotted on each graph. Variance-weighted 
least-squares regression was used to test whether the linear trend was significant or not to determine 
whether there was an increase or decrease over the weeks for each dipstick and laboratory result for 
each analyte measured. Goodness-of-fit chi2 was used to test whether the single population fitted the 
hypothesised distribution. Then the model fit chi2 was used to compare the weeks to each other 
(across categories). 
In summary, the Laboratory High-throughput Protein (LP), LifeAssay Protein Dipstick (DP), 
Laboratory High-throughput Creatinine (LC) and Laboratory High-throughput Calcium (LCa) trend 
showed no significant value for the co-efficient, goodness-of-fit chi2, and model chi2. It is possible 
that the small sample size of 14 patients over the weeks, resulting in a total of 56 samples analysed, 
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affected the results and a pattern could not be inferred. There was a high degree of variation in the 
standard deviations in each graph, which is mostly the result of a small sample size with large 
variations. Despite the lack of non-significance, it is noted that, both the laboratory and dipstick 
protein measurements showed a higher protein value for week 32 in both analyses compared with the 
other weeks. This observation is important and could be explained by the fact that pre-eclampsia 
affects pregnant women mostly in the 3rd trimester of their pregnancy. As the kidney and liver is most 
at risk during pre-eclampsia the high protein values observed in the latter weeks of gestation reflect 
kidney impairment. 
It was noted for the Calcium measurements, that an increase of Calcium was observed following 
week 1 until a plateau is reached. This observation is consistent and could be justified through the 
fact that pregnant women receive a consistent dose of calcium supplement throughout their 
pregnancy.  
However, the LifeAssay Creatinine Dipstick (DC) had a significant value for the co-efficient and 
model chi2. It is possible that this was the result of subjective interpretation. For the creatinine 
dipstick, it was decided to over-estimate the value rather than under-estimate it, when it was unclear 
which colour it was. Owing to over-estimation, it was possible that the pattern formed as a result and 
it was indicated to be significant for a linear trend. 
4.2 ELISA-based Adipsin evaluation 
As mentioned in Chapter 1, Section 1.6, a relationship between the complement system and PE was 
demonstrated. As measurements of complement activation products were shown to be increased in 
PE pregnancies compared with normal pregnancies, this observation was explored further in this 
study. Thus, the objective was to determine whether Adipsin or Complement Factor D (CFD) could 
be measured via ELISA using urine samples that were frozen at -80oC for 3+ years. A pilot study was 
carried out to evaluate Adipsin using an ELISA assay to discuss future implications and how the assay 
could be improved. 
The standard curves that were generated for each plate had a relatively high but still low actual R2 
value. Certain data points were remove to test their effects. It was noticed that, when the 40ng/ul 
concentration and associated optical densities (OD) value were removed, the two standard curves 
improved considerably. It was therefore assumed that, when the stock solution was used to create the 
160ng/ul and then the 40ng/ul, the values were not pipetted correctly or the bottle was not shaken 
enough. Evidently, a few errors occurred at this stage and, because they was consistent across both 
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plates, it was decided to remove them and use the adjusted standard curve also to calculate the 
concentrations.   
Using the first standard curve, the concentrations were calculated from the OD values. When the 
values came up negative, the adjusted standard curve was applied. A few values became positive but 
were low values for the concentration. Despite the high R2 value for each standard curve, it was not 
possible to calculate positive concentrations for the OD values which were already low.  
The %CVs should be calculated from the calculated concentrations. In this case, the calculated 
concentrations were mostly negative, from both the original results and the adjusted results. There 
were two reasons why the concentration values were negative in this scenario. The one reason was 
that, because the urine samples were stored for so long, it was possible that the Adipsin had degraded 
over time. The other reason was that the ELISA assay was not sensitive enough for small 
concentrations of Adipsin, especially in urine. In the protocol (Appendix G) under the sample 
collection and storage section, there was not an exclusive section on urine samples. They did however 
mention that for samples not listed in the manual, a pilot study into the validity of the assay was 
required which we decided to do for the long term stored urine samples. This therefore emphasises 
that there should be more research studies carried out on the impact of sample handling, processing 
and storage conditions on urine samples for the measurement of bio-marker levels because there is 
no gold standard to examine the impact of storage time on bio-marker levels. Following from this 
limitation, a future study re-measuring Adipsin over time from aliquots of a single sample would 
provide a lot more information about why the value is so low. In addition, comparing the measurement 
of Adipsin in fresh samples as a baseline or reference is also essential. Since this study not have a 
baseline measurement because existing data and samples were used, the reason why the concentration 
values were low could not be assumed correctly. However, OD readings were obtained, which 
indicates that the ELISA assay can be used to measure Adipsin in urine but the assay needs to be 
validated further to account for the low concentrations.  
It was decided still to calculate the %CV from the OD values to assess how well the assay was 
processed. Plate 1 had a range of %CV values from 0.841% to 22.701%. Plate 2 had a range of %CV 
values from 1.797% to 48.951. Intra-assay %CVs (an average value calculated from the individual 
CVs) should be <10%. The scores obtained reflected the performance of the user who was handling 
the assay. The %CVs that are >10% reflect poor pipetting technique of the user. It is the norm to use 
%CVs of the concentrations, but here the OD values %CVs have been emphasised. The average %CV 
for plate 1 was 6.6% and plate 2 was 9.2%. They were both <10% which indicates good pipetting 
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technique. The average %CV across the plates was 7.9% which indicates consistent pipetting across 
both plates. 
The Inter-Assay (plate-to-plate consistency) %CV of <15% is generally acceptable. In this scenario, 
inter-assay must be calculated using 8 repeats across 3 plates of high and low values. This was not 
included as the aim was to assess whether Adipsin could be measured and what further measures can 
be considered, not whether the plate-to-plate consistency was correct. The next step for validation 
would be to account for the small values and the plate-to-plate consistency once the small values have 
been accounted for.  
4.3 Evaluating the pre-analytic effect of pre- and post-storage conditions 
and processing of fresh urine samples 
Important limitations for this study were the lack of baseline measurements as well as lack of data 
relating to the pre-analytical variables, which made it difficult to infer whether differences observed 
because of storage or differences in assay methodologies and processing. Also, when it comes to urine 
analysis, a gold standard for processing needs to be followed, which includes centrifugation prior to 
storage of aliquots. The urine samples that formed part of this cohort had been collected in busy 
clinics in hospitals following a standardised protocol but it was not possible to account for the pre-
analytical variables and the time for which the samples were stored because they were stored for 3+ 
years prior to long-term storage at NSB and the centrifugation steps that form part of the gold standard 
method were lacking. Therefore, it was not possible to determine whether these types of pre-analytical 
variables have an effect of analytes over time. Furthermore, it was not known whether the different 
sites that collected the urine samples adhered to the standardised protocol because of contributing 
factors such as availability of the -80 oC freezer, transport and access to fridges. It was necessary to 
gain some insights into how different, possible conditions could affect analytes in urine samples over 
time. In this case, it was decided to use the gold standard as a reference and test conditions where the 
samples were stored at 4oC in a fridge, stored at room temperature (24oC) or were centrifuged 
according to the gold standard and how this could affect the outcome on selected analytes.   
Accordingly, the Wilcoxon Signed-Rank Test was used for this investigation. Each group (Group 2, 
3 & 4) was compared with the reference group (Group 1 – gold standard) using an average of the 19 
patients for each analyte. Twenty consenting patients participated but the clinical laboratory did not 
measure all of the analytes for one of the patients, therefore that patient was excluded. The Wilcoxon 
Signed-Rank Test examines how different the groups are in relation to the reference group and 
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accounts for skewed data sets. The data were a matched data set (measurements were from the same 
individuals but under different conditions). 
Using the Wilcoxon Signed-Rank Test, the median for Creatinine, Calcium and Protein for both 
Group 1 and 3 were significantly different from each other using Group 1 as the reference. Therefore, 
Group 3 was significantly different from Group 1. 
Group 1 was centrifuged, then stored at -80oC for 3 months as the gold standard. Group 3 was 
centrifuged, then was stored at room temperature (24oC) for 48 hours and then stored at -80oC for 3 
months. The fact that the samples were left at room temperature for 48 hours was most likely the 
contributing factor for their Creatinine, Calcium, and Protein measurements being significantly 
different from the gold standard. It is known that Albumin and Urea are quite consistent or stable as 
analytes, which is probably why their measurements for Group 3 were not significantly different from 
the gold standard.  
4.4 Summary 
Exploratory pilot studies were used for all three objectives to understand different aspects of urine 
sample collection, handling, and storage. Objective 1 was to consider how the possible use of 
dipsticks to diagnose PE would compare with laboratory measurements and whether, although the 
samples had been frozen for 3+ years, measurements could still be reliable despite the fact that 
dipsticks are generally assumed to be not as good as high-throughput measurements. In the case of 
comparing the Siemens protein dipstick to the newly developed LifeAssay protein dipstick, the 
measurements were significantly similar, which was expected because the process was under the 
researcher’s control. The LifeAssay protein dipstick results were not similar to the laboratory results. 
Similar results were found for the creatinine measurements between the LifeAssay dipstick and the 
laboratory measurement. Thus, more research and evaluation studies are required for the newly-
developed creatinine LifeAssay Protein Dipstick, which was the essential point of this pilot: to 
determined how this study’s observations could help improve gaps and issues in the larger study.  
Objective 2 was to consider the bio-marker, Adipsin. The aim was to determine whether Adipsin 
could be measured using the ELISA assay despite the assay not being validated for urine samples, 
especially urine samples that were frozen for 3+ years. The Adipsin could be measured, but the OD 
values were very low, which resulted in negative concentration values. There were many reasons why 
the values could have been negative as explained in Section 4.2. The most important finding from 
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this objective was that, despite the samples being stored for 3+ years, Adipsin could be measured 
using the ELISA assay.  
Objective 3 was to consider how sample collection and handling can affect the results of the 
measurements. It was noted that Group 3, which was stored at room temperature, was the most 
affected and therefore deviated from the gold standard for Creatinine, Protein and Calcium.  
Each objective of this study provided some insight into sample collection, handling, processing and 
storage and how each step of the process can have an impact. These insights also led to understanding 
of the limitations of this pilot study and possible future studies. 
4.5 Limitations and Future Studies 
In addressing Objective 1, because of the small sample size, it was not possible to infer correctly 
whether the dipsticks were similar to the laboratory measurements or not. A larger sample size would 
have given a better understanding of the results. Thus, in a future study, a larger amount of data would 
be the most beneficial. One patient that had results from every week was needed to obtain a consistent 
result for the trend analysis, but only 14 patients were found that had results from each week. This 
was a limitation because if there were more patients across the weeks, maybe 100 patients, then it 
would have been possible to see a clearer pattern. Another potential limitation was the possibility that 
some of the LifeAssay Dipsticks could be faulty since it was newly-developed and under evaluation. 
If so this could have had a major effect on the results.  
In objective 2, the small sample size was also a limitation. Another limitation was that a measurement 
at different time intervals was not available. Therefore, a future study include re-measuring Adipsin 
over time from aliquots of a single sample. This would provide a lot more information about why the 
values measured were so low. A future study should also compare the measurements of Adipsin over 
time intervals with the measurement of fresh samples as a baseline or reference and also include a 
high and low control which this study lacked.  
Objective 3 was to consider how sample collection and handling can impact the results of the 
measurements. The main limitations were that there was no baseline measurement against which to 
comparisons, and there were no interval measurements over the 3 months. Both of these limitations 
could be used in a future study as this would give more insights into the impact of sample collection 
and handling. 
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4.6 Conclusion 
In conclusion, the results demonstrated that when studying bio-markers in the context of long-term 
stored samples, the impact of urine processing and duration of storage on bio-marker levels is 
essential. It is also methodologically challenging because of various measurements over various time 
points over an extended time period. Limitations such as sample size, lack of baseline measurements, 
pre-analytical variables, and assay variation or drift could affect results, which makes it difficult to 
infer differences related to storage time from differences related to biological or assay variability and 
requires further investigation. Despite these limitations, this exploratory study did help to establish 
priorities for the larger study in terms of the analytes selected to be measured, in improving the final 
research design, and determining the best data collection and analysis methods for future studies. 
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Appendices 
List of appendices attached: 
A: WHO CAP SOP 
B: H3A SOP Sample transport and shipping 
C: Project Info and Consent 
D: SOP Urine CREATININE ChemPath 
E: SOP Urine CALCIUM ChemPath 
F: SOP Urine TOTAL PROTEIN ChemPath 
G: ELISA Kit for Complement Factor D (CFD) 
H: SOP Urine ALBUMIN ChemPath 
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